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ABSTRACT 	  
MUTUAL REINFORCEMENT BETWEEN TELOMERE CAPPING AND CANONICAL 
WNT PATHWAY ACTIVITY IN THE INTESTINAL STEM CELL NICHE  
Ting-Lin Yang  
F. Bradley Johnson 
 
Mice lacking telomerase (e.g. mTR-/-) for several generations develop dysfunctional 
telomeres and severe gastrointestinal pathology. Intestinal stem cell (ISC) abnormalities 
in late-generation mTR mice have been described, and we set out to characterize it in 
more detail. Expression profiling of mTR-/- crypts and an unbiased gene set enrichment 
analysis revealed broadly decreased expression of Wnt pathway genes in crypt epithelia 
and underlying stroma. We describe abnormalities in the Wnt-dependent intestinal stem 
cell (ISC) niche in these mice, including decreased expression of ISC marker genes 
Ascl2, Lgr5, and Sox9.  The importance of these changes was revealed by rescue of 
crypt apoptosis along with Ascl2 and Sox9 expression upon treatment of mice with Wnt 
pathway agonists, as well as enhanced survival and Lgr5 expression in cultured mTR-/- 
intestinal crypts.  Rescue was associated with reduced telomere-dysfunction induced 
foci (TIFs) and anaphase bridges, indicating improved telomere capping, which 
correlates with upregulation of Trf2 and Pot1a, encoding capping proteins in the shelterin 
complex.  Similar gene expression changes, and rescue by Wnt pathway activation, 
were observed in human cells suffering from telomere dysfunction, including those 
derived from dyskeratosis congenita and Werner syndrome patients.  These findings are 
independent of previously suggested connections between Wnt and the catalytic 
component of telomerase, TERT, and demonstrate a mutually reinforcing relationship 
between telomere capping and Wnt signaling, which may provide new approaches to 
diseases characterized by telomere dysfunction. 
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CHAPTER 1: INTRODUCTION 
The idea that a limited ability of cells to divide might contribute to the 
pathogenesis of age-related diseases was first raised by Hayflick and Moorehead 
a half century ago.  It was based on their observation that human fibroblasts 
have a finite replicative capacity when cultured in the laboratory, a process 
termed cell senescence (1, 2).  It is now known that a major factor limiting cellular 
replicative lifespan is the shortening and consequent dysfunction of telomeres, 
structures that normally cap and protect the ends of chromosomes.  And 
because telomeres shorten with cell division and age in most human tissues, it 
has been hypothesized that such shortening might lead to loss of telomere 
function and thus be a fundamental driver of aging.  Although an attractive and 
seemingly simple concept, it has taken decades to begin to assess potential 
roles for telomere dysfunction in human aging.  Recently, substantial evidence 
has emerged supporting such roles, but the details are proving more complex 
than perhaps envisioned originally.  Furthermore, many questions remain 
concerning the degree to which telomere biology contributes to human age-
related pathologies, and concerning underlying mechanisms.  We will begin with 
brief descriptions of telomere structure and function, and findings from cultured 
human cells and from mice.   
TELOMERES AND TELOMERASE 
Telomere Structure and Function  
Telomeres are the structures at chromosome ends and are composed of 
tandem-repeats of DNA sequences ((5’-TTAGGG-3’)n in all vertebrates including 
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humans) and associated factors such as the shelterin proteins.  When fully intact, 
telomeres perform several functions collectively known as “capping” (3).  First, 
capped telomeres protect chromosome ends from degradation by exonucleases.  
Second, they prevent chromosome ends from being recognized as generic 
double strand breaks and thus eliciting cell cycle checkpoint responses leading to 
either stable cessation of cell division (cell senescence) or programmed cell 
death (apoptosis).  Third, capped telomeres inhibit DNA repair reactions that 
could otherwise lead to deleterious products, e.g. end-to-end chromosome 
fusions.  In addition to these well-established functions, recent evidence indicates 
that telomere status also impacts gene expression on a broad scale.  Capped 
telomeres are thus critical for genome stability, for the progression of cell division 
and survival, and for normal cell physiology. 
An important contributor to capping is the length of the telomere repeat 
DNA, and critical shortening leads to uncapping.  Adult human telomeres are 
approximately 5 – 15 kb in length, and end with 3’ single-stranded overhang 
extending roughly between 50 and 300 nucleotides.  For several reasons, 
telomere length can shorten through rounds of cell division.  Shortening is most 
commonly attributed to the so-called “end replication problem”, which is the 
inability of the standard replication machinery to generate a DNA copy extending 
all the way to the 3’ terminus of the chromosome (4, 5).  This is because the 
telomere strand that ends in the 3’ direction (the so-called G-strand) must be 
copied by lagging strand synthesis, and each Okazaki fragment begins with a 12-
14 nt long RNA primer that is ultimately removed.  For the final Okazaki 
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fragment, this leaves a terminal gap that cannot be filled by additional DNA 
synthesis.  However, actual measured rates of telomere shortening, e.g. 50 – 
100 bp per cell division in cultured human fibroblasts, exceed those predicted by 
the simplest version of the end replication problem, in which the RNA primer is 
laid down at the very end of the telomere.  Recent measurements indicate that 
final RNA primer is actually located ~70-100 nt internal to the very end, helping to 
explain the faster rate of telomere shortening (6).  Furthermore, exonucleolytic 
processing events lead to shortening of the other telomere strand, i.e. the C-
strand, following its replication.  The C-strand is copied by leading strand 
synthesis, which can yield a full copy, but subsequent 5’-to-3’ exonucleolytic end-
resection occurs to generate a single-stranded 3’ overhang, thus shortening the 
telomere (7).  This makes sense, because the 3’ overhang is essential for 
telomere capping.  Thus cells intentionally use mechanisms to replicate and 
process telomere ends that promote capping of longer telomeres, even though 
they can ultimately contribute to uncapping via shortening.   
Additional, less telomere-intrinsic, mechanisms also contribute to telomere 
shortening.  First, oxidative damage can accelerate telomere shortening, 
apparently by increasing the level of single-stranded breaks in telomeres, which 
are converted into double-stranded breaks during replication (8-10).  Similarly, 
high levels of UV light can cause telomere shortening apparently by inducing 
DNA oxidative damage (11).  However, even though telomeres are particularly 
susceptible to UV-specific damage, primarily the formation of cyclobutane 
pyrimidine dimers (CPD), elevated telomere CPD may not lead to enhanced 
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shortening (12).  Second, telomeres are intrinsically difficult to replicate, similar to 
so-called fragile sites and perhaps due to formation of DNA secondary structures 
that impede replication.  Thus conditions that lead to replication stress, e.g. 
activation of oncogenes, RNA bound to DNA ahead of the fork, and limiting levels 
of dNTPs, can lead to sudden and dramatic telomere shortening caused by 
broken replication forks (13-16).  To what extent the telomere-extrinsic and 
telomere–intrinsic mechanisms of shortening described here and above are 
modulated by the environment and with age to contribute to telomere losses in 
aging tissues is currently not well understood, but they have the potential to have 
significant impacts. 
In some tissues telomere shortening is countered by the enzyme 
telomerase.  Telomerase is a reverse transcriptase that carries its own RNA 
template, which it uses to encode repeat DNA added to the 3’ end of telomeres, 
and which is followed by lagging-strand synthesis to generate the complementary 
strand of the telomere duplex (17).  However, in most human tissues telomerase 
activity is present at levels insufficient to prevent age-related telomere losses. 
Also critical for capping are several factors that associate with telomere 
DNA.  In humans, central players are the six shelterin complex proteins, TRF1, 
TRF2, RAP1, TIN2, TPP1 and POT1 (18), and the three components of the CST 
complex, CTC1, STN1 and TEN1.  TRF1 and TRF2 each bind as homodimers to 
duplex telomere repeats in a sequence-specific fashion.  POT1 binds the 3’ 
single-stranded overhang, also in a sequence-specific fashion, and the bridging 
of TRF1/TRF2 to POT1 by the TIN2 and TPP1 proteins yields a protein complex 
5	  
that targets the telomere DNA with high affinity and specificity.  All six shelterin 
proteins exist in mice, with the exception of Pot1 having two forms in mice, Pot1a 
and Pot1b, which have different functions: Pot1a appears to play a more 
important role in telomere capping and suppresses the DNA damage response 
while Pot1b regulates length of the 3’ telomeric overhang (19). Shelterin uses its 
components in different ways to suppress ATM and ATR-dependent DNA 
damage responses and to inhibit DNA break repair pathways (20, 21).  One 
particularly remarkable way is the TRF2-dependent assembly of the telomere 
end into a t-loop, formed by the invasion of the 3’ ss-overhang into the base of 
the telomere repeats to form a D-loop (or possibly a Holliday junction), thus 
obscuring the end (22, 23).  Shelterin also helps recruit and regulate the activity 
of many additional proteins that maintain telomere structure and function.  
Remarkably, among these are proteins involved in recognizing and repairing 
DNA breaks, but under the influence of shelterin at capped telomeres these 
functions are tamed and redirected toward telomere maintenance. The CST 
complex plays a general role in DNA replication, facilitating restart of damaged 
replication forks (24).  This is particularly important at telomeres, because they 
are generally each replicated by only a single fork, in contrast to other genomic 
regions, which, if their replication by one fork fails, can often be replicated by a 
convergent fork from a neighboring origin of replication. Furthermore, the CST 
complex also facilitates fill-in of the C-strand after elongation of the G-strand by 
telomerase (25).  Both the shelterin and the CST complexes also play roles in 
regulating telomerase action at telomere ends (26). 
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Although it is clear that inherited mutations in telomerase, shelterins, and 
other telomere maintenance factors can cause premature telomere dysfunction 
and thus diseases (some of which resemble natural age-related pathology; see 
below), there is little evidence that age-related changes in the activity of these 
factors underlie normal diseases.  Whereas such changes are possible, and are 
worthy of investigation, current understanding suggests that damage to the 
telomeric DNA itself (e.g. critical shortening) with age is a more likely primary 
driver of age-related telomere defects.   
Measurement of Telomere Lengths 
Different techniques are used to measure telomere lengths.  Because of 
their relative ease and ability to measure small amounts of material, real-time 
PCR-based approaches that measure telomere repeat content in comparison to 
a single copy gene (T/S ratio) are most common (27, 28).  However, this 
provides only a mean telomere length measurement, and because there is strong 
evidence that the shortest telomere or telomeres are more important in driving 
cell senescence than mean telomere length, this is a potential drawback (29-32).  
This also holds true for “flow-FISH”, which measures the mean telomere length 
per cell (33).  Other approaches used less widely primarily due to their labor-
intensiveness, are classical Southern analysis of chromosome terminal restriction 
fragments, and Q-FISH, which uses quantitative fluorescence microscopy to 
measure individual telomere intensities in metaphase chromosome spreads (34, 
35).  These can reveal information about length distributions, though Southern 
analysis is not sensitive for detecting extremely short telomeres and is also 
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affected by inter-individual and inter-telomere variability in subtelomeric 
sequences.  The Southern approach can be more precise than real-time PCR, 
but in typical use they yield similar findings for mean length (36, 37).  A new 
automated method, HT Q-FISH, provides benefits of Q-FISH in a high-throughput 
format, although it required dissociated cells and also cannot detect chromosome 
ends lacking all (or almost all) telomere repeats (38-40). 
Telomerase Structure and Function 
Telomerase is a ribonucleoprotein complex composed of the enzymatic 
reverse transcriptase protein TERT and the RNA template TR (also known as 
TERC), which encodes the telomere repeat. Multiple accessory proteins have 
been implicated in telomerase assembly, function, and localization, but in vitro 
analyses have determined that TR RNA and TERT together are sufficient for 
synthesizing telomeric DNA repeats (41, 42). The first step of telomeric DNA 
synthesis requires base pair formation between TR and the 3’ telomeric G-rich 
overhang within the active site of TERT. The second step involves the addition of 
nucleotides onto the 3’ telomeric end to elongate telomeres. Telomerase then 
translocates to the new 3’ overhang to restart the telomeric synthesis process 
again (reviewed in (17, 43)). Over 30 proteins have been proposed to associate 
with telomerase, but the heart of the catalytic core of human telomerase is 
composed of two copies each of TERT, TR, and dyskerin (44). Telomerase likely 
exists in different conformations (reviewed in (45)), and the secondary structure 
of hTR seems to be important for TERT tethering and telomerase interaction with 
accessory proteins, including dyskerin, hGAR1, NHP2, NOP10, and TCAB1 (46).  
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Telomerase activity may be regulated by several different mechanisms, 
and levels of telomerase expression do not always correlate with its activity. Both 
hTR and hTERT are required to be expressed in the cell. In fact, hTR is generally 
ubiquitously expressed, even in cells without telomerase activity (47). hTERT 
expression exhibits more tissue specificity and seems to be the rate-limiting 
factor for telomerase activity. Indeed, telomerase activity can be induced when 
hTERT is overexpressed in mortal cells without telomerase activity (41, 48). 
Telomerase activity can be measured by the TRAP assay, a PCR-based 
method compatible with crude cell or tissue extracts (49). Telomerase present in 
the extract extends a synthetic substrate primer, and the extended products are 
then amplified by PCR.  On an electrophoretic gel, reaction products of the TRAP 
assay have a distinctive banding pattern, which corresponds to the discrete 6 bp 
additions of telomeric repeats by telomerase, and can thus give some information 
for both overall activity and approximate levels of processivity of the telomerase 
activity.  A real time PCR-based assay also exists, which is convenient to run on 
large numbers of samples but gives information related only to overall activity 
(50).  Based on early TRAP assays, telomerase activity was detected in almost 
all cancer cells and in developing human embryonic tissues and germ cells but 
not in quiescent or terminally differentiated somatic cells (49, 51, 52). During 
embryonic development, telomerase activity disappears in brain and bone 
extracts after 16 weeks of gestation and progressively shuts off in other tissues 
(adrenal gland, muscle, lung, skin, and liver) during fetal development.  Later 
studies showed that many tissues that naturally undergo regeneration express 
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telomerase activity, including the esophageal epithelium (53), intestinal 
epithelium (54), basal keratinocytes (55), cycling endometrium (56, 57), and 
hematopoietic stem cells (58). It is now apparent that many adult human stem 
and progenitor cells exhibit telomerase activity. Telomerase activity is present in 
the proliferative and regenerative zones of the human skin and hair follicles (59, 
60). Similarly, in the intestine, where a crypt-villus axis exists to reflect stem to 
progenitor to differentiated cell states, telomerase activity is restricted to the crypt 
base with no detectable activity in the villi (54).  Proliferating spermatozoa have 
constitutive telomerase activity throughout the entire lifespan.  Telomerase 
activity can also be activated in other physiologic states, such as growth-
stimulated lymphocytes and uroepithelial cells (61, 62).  
Telomerase activity may also be regulated by hTERT mRNA alternate 
splicing and hTERT localization. In the fetal kidney, full length hTERT mRNA is 
expressed until gestational week 15, when telomerase activity is present. After 
week 15, when inactive splice variants of hTERT are expressed instead of full-
length hTERT transcripts, telomerase activity is no longer detectable (63). 
Likewise, lymphocytes can control telomerase activity independent of hTERT 
protein levels. Telomerase activity-positive thymocytes and telomerase-activity 
negative peripheral T cells express hTERT protein levels at a comparable level. 
Upon CD4 T cell activation, telomerase activity can be induced by the nuclear 
translocation of hTERT in a phosphorylation-dependent manner (64).  
Cellular Consequences of Telomere Dysfunction 
10	  
The cellular consequences of telomere shortening and uncapping are 
manifold and can vary according to cell type.  Uncapped telomeres lose their 
ability to be masked as double strand breaks, and so a proximal response is the 
activation of the ATM and ATR-dependent DNA damage responses (31, 65, 66).  
Indeed, one way to detect uncapped telomeres in cells and tissues is using the 
microscopy-based TIF (telomere dysfunction-induced focus) assay, which 
visualizes the colocalization between telomere ends and DNA damage response 
(DDR) factors (e.g. γH2AX or 53BP1) (66, 67).  A remarkable feature of 
telomeres is their capacity to resist DNA repair, even after levels of uncapping 
sufficient to activate DNA damage responses (which can occur before all 
telomere repeat DNA is lost, thus allowing aspects of telomeric character to 
persist; see below) (68, 69).  This suppression of repair leads to persistent DDR 
signaling that consolidates further cellular responses.  One general cellular 
response is apoptosis, which has relatively simple consequences because the 
cell in question is eliminated.   Apoptosis seems most common in cell types 
whose corpses are easily disposed of, for example skin and intestinal epithelial 
cells, which are normally and efficiently shed into the environment, or 
lymphocytes, which are efficiently cleared by macrophages.    
Cell senescence is another general cellular response to uncapped 
telomeres, wherein the cell survives but undergoes substantial changes in its 
physiology, including stable arrest of its cell cycle.  Senescent cells are thus 
marked by a number of phenotypic changes - for example expression of 
lysosomal senescence-associated β-galactoside activity, increased levels of 
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heterochromatic proteins such as macroH2A, increased levels of cell cycle 
inhibitors such as p21 and p16 - but no known marker is perfectly sensitive or 
specific for detecting senescence in all settings (70).  Senescence is a 
programmed response to diverse stresses, including telomere uncapping as well 
as oncogene activation, oxidative damage, ionizing radiation, and changes in 
chromatin structure (70).  The program is thought to have evolved to prevent the 
growth of pre-cancerous cells into more advanced tumors, and a large body of 
evidence strongly supports this view, although it also appears to play important 
roles during development and in anti-viral responses (71-73).  Senescent cells 
may be cleared by the immune system, but in some cases can persist. For 
example melanocytes in benign nevi (i.e. skin moles) appear to be in a 
senescence state for decades (74).  Remarkably, there is some evidence that 
seemingly telomere-independent stresses that induce senescence (e.g. oxidative 
stress; activated oncogenes) may actually lead to senescence, at least in part, by 
their effects at telomeres.  For example, oncogene-induced replicative stress 
may be particularly pronounced at telomeres, and any resulting broken 
replication forks may be least likely to be repaired at telomeres, leading to their 
premature shortening.  Thus a global stress is transformed into a more telomere-
focused one (16).   
Senescence is thought to contribute to age-related pathology in at least 
two ways.  First, senescence of stem cells may limit their capacity to produce 
progeny needed to maintain tissue homeostasis.  Support for this idea includes 
mouse experiments in which genetic inactivation of p16INK4a, a cyclin kinase 
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inhibitor that enforces cell senescence by preventing cell cycle progression, was 
shown to prevent age-related stem cell deficits in the brain, pancreas, and bone 
marrow (75-77).  Second, senescent cells are thought to contribute to aging by 
having dominant effects on their surrounding cells.  Central to this idea is the so-
called senescence-associated secretory phenotype (SASP), substances 
released by senescent cells, including matrix metalloproteinases and 
inflammatory cytokines that can have profound tissue effects (78-80).  Direct 
support for the contribution of senescent cells to tissue pathology was 
demonstrated by inducing selective apoptosis of p16-expressing (i.e. senescent) 
cells in a mutant BubR1 mouse model.  The BubR1 mutant accumulates an 
unusually high level of senescent cells, and elimination of the cells alleviated 
pathology in several tissues (81).  It will be important to determine if these 
findings translate to telomere-induced senescence and to natural aging. 
Shortened and uncapped telomeres have other effects, which may 
contribute to apoptosis and senescence but are also separate from these 
processes and might contribute independently to aging.  First, they lead to 
dramatic changes in gene expression that may contribute to cell and tissue 
dysfunction.  The mechanisms underlying these changes are under active 
investigation, and appear to involve widespread changes in chromatin 
architecture that suggest important communication between telomere events and 
the rest of the genome (82-84).  Of particular interest, evidence is emerging that 
even before a telomere has become short enough to be uncapped, its shortening 
can influence gene expression (85, 86).  Therefore changes in telomere lengths 
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with age may contribute to changes in gene expression prior to the onset of 
apoptosis or senescence.  A second set of important changes include 
compromised mitochondrial biogenesis and function (87-89).  Studies in 
telomerase-deficient mice with critically shortened telomeres showed these 
effects are mediated in large part by p53-dependent inhibition of the Pgc1a and 
Pgc1b transcriptional co-activators, and are accompanied by other broad 
changes in metabolism also regulated by these co-activators (90).  Interestingly, 
these changes occurred in several tissues, including those with very low cell 
turnover (e.g. myocardium), suggesting these mechanisms may connect 
telomere changes to aging of post-mitotic cells.  And third, uncapped telomeres 
can lead to inter-telomere recombination.  This can take the form of homologous 
recombination-dependent telomere lengthening, which occurs at undefined rates 
in some normal cells and is used as an alternative to telomerase for telomere 
length maintenance in about 10% of cancers (91, 92).   Alternatively, and more 
ominously, inter-telomere recombination can take the form of non-homologous 
end joining-mediated fusions between telomere ends. Such fusions can lead to 
chromosomal aneuploidy, because at mitosis the resulting dicentric 
chromosomes can break at sites outside the point of fusion or are not disjoined, 
and thus unequal chromosomes complements are inherited by the daughter 
cells.  This can lead to cell death, senescence, or to cancer (see below).  
However, even though it is sometimes implied in the scientific literature that such 
fusions are a frequent outcome of telomere uncapping and are a primary cause 
of senescence, in normal human cells such fusions occur at a minority of 
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uncapped telomeres and are not required for senescence (29, 93, 94).  Indeed, 
there appear to be intermediate degrees of telomere uncapping sufficient to 
activate partial DNA damage responses that drive senescence, but which occur 
before a telomere has become further uncapped and fusogenic (29, 95).   Cells 
that have lost responses to intermediate levels of uncapping (e.g. p53-deficient 
cells) can continue to shorten telomeres to the point of full uncapping, leading to 
fusions and thus genome instability that can drive cancer.   
Given that the loss of replicative capacity was the original attribute that led 
to the identification of cell senescence, it has been natural to assume that the 
transition from a replicative to a non-replicative state is an essential feature of 
senescence.  This is consistent with the idea that a key purpose of the 
senescence program is to inhibit the growth of pre-cancerous cells.  However, 
recent evidence suggests that even cells that are already post-mitotic can display 
other features of senescence.  As such, senescence might be viewed as a 
programmed response of cells to particular stresses.  For example, elevated 
markers of oxidative and DNA damage, and senescence-associated changes in 
chromatin and gene expression including upregulation of the inflammatory 
cytokine IL-6 and of the cyclin kinase inhibitors p16 and p21 have been reported 
in neurons of aged mice (96).   It is possible that telomere dysfunction contributes 
to this type of neuronal senescence, because the markers were more 
pronounced in telomerase-deficient mice.  Furthermore persistent DNA damage 
foci in the neurons of normal mice exposed to ionizing radiation occur 
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preferentially at telomeres, indicating telomeres may be key transducers of 
stresses into senescence responses even in post-mitotic cells (68).   
Proof that telomere shortening is an important cause of cultured human 
cell senescence was demonstrated by the bypass of senescence upon 
upregulation of telomerase activity via artificial overexpression of hTERT (97).  
hTERT expression was sufficient to provide telomerase activity, and thus 
telomere lengthening, because other telomerase components (e.g. hTR) were 
already expressed naturally.  Although potential extra-telomeric roles for hTERT 
have been reported, e.g. in mitochondria, DNA repair, stem cell maintenance, 
and modulation of Wnt signaling (46, 98-100), some of these are controversial 
(101), and regardless it is the extension of telomere length that most likely 
underlies the bypass of senescence.  Strongly supporting this idea is the 
demonstration the degree of telomere lengthening following a transient pulse of 
telomerase activity correlates with subsequent cell replicative lifespan (102).  
However, we want to emphasize that even though telomere shortening clearly 
drives the senescence of cultured cells, it is not yet clear to what extent 
senescence in humans is a telomere-driven process, and more work needs to be 
done to determine whether senescent cells, particularly those driven into 
senescence by telomere dysfunction, contribute to age-related pathology in 
humans.   
Telomeres and Aging, and Telomere Syndromes 
In the normal human population, telomere lengths range from 
approximately 5 to 15 kb and change during pre and postnatal development and 
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aging. There is ample support for the idea that telomeres tend to shorten with 
age in most human tissues, even including tissues with low levels of cell turnover 
such as brain (103) (104-106).   
Telomere lengths are highly similar among tissues within an individual in 
utero and soon after birth (107, 108). However, they vary among individuals but 
are not different between male and female newborns, suggesting that increased 
variability in length between individuals and genders arises from different rates of 
telomere attrition later in life.  After birth, telomerase activity is repressed in most 
somatic cells, and thus telomeres shorten during growth to adulthood.  
Importantly, there is some telomerase activity in stem and progenitor cells, which 
helps counter but not prevent shortening.  Telomeres shorten most during the 
rapid growth to adulthood, around 1kb from birth to 4 years of age and 
decreasing to less than 100bp per year thereafter in leukocytes (109). They 
shorten in rough proportion to the proliferative rate of the tissue, e.g. telomeres 
shorten more rapidly in peripheral blood leukocytes than in skeletal muscle, but 
shortening rates may also be influenced by differences in levels of telomerase 
among tissues.  Telomere lengths are nonetheless correlated among tissues 
when making comparisons between people, i.e. a person with longer-than-
average telomeres in skeletal muscle will also have longer-than-average 
telomeres in leukocytes (110, 111).  
Within a lineage of cell types, telomere lengths correlate positively with 
telomerase expression and activity, and in stem cells where telomerase 
expression is high, telomere lengths are also the longest. Stem cells have longer 
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telomeres than progenitor cells, which in turn have longer telomeres than 
differentiated cells. Q-FISH analyses of murine skin, intestine, testes, cornea, 
and brain found the longest telomeres to be located in stem cell compartments, 
with progressively shorter telomeres towards the more differentiated cell 
compartments (112). Stem cells also undergo telomere attrition with age, despite 
expressing telomerase activity. Telomeres in stem cells from two year old mice 
are significantly shorter than from two month old mice, which may be explained in 
part by the concurrent decline in telomerase activity with age (112, 113). 
Similarly, in humans, despite the presence of telomerase activity in stem cells, 
telomere attrition still occurs in stem cells with age – hematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSCs) have shorter telomeres with age 
(114, 115).  However, the converse seems to be true in male germ cells – 
telomeres are longer in spermatozoa produced by older men (116).  
There is clear evidence that telomeres shorten with age, but is the 
shortening during the lifetime of an individual enough to contribute to telomere 
dysfunction in aging mammals? Indeed, there exists direct evidence that links 
aging and uncapped telomere in primates. There is an exponential increase in 
the frequency of dysfunctional telomeres in baboon dermal fibroblasts with age, 
as measured by TIFs. Correspondingly, there is also an exponential increase in 
cellular senescence and p16INK4a expression in the baboon skin fibroblasts with 
age, with 80% of the senescent fibroblasts positive for TIFs (117). Several rare 
genetic diseases displaying premature onset of some features of aging, called 
progeroid disorders, are associated with defects in telomere maintenance 
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factors.  Understanding the mechanisms underlying these diseases can therefore 
provide insight into potential contributions of telomere dysfunction to age-related 
pathologies.   
The first progeroid disease to be connected clearly to telomeres is 
dyskeratosis congenita (DC) (118).  DC was originally defined by a classical triad 
of clinical signs including oral leukoplakia, dystrophic nails, and skin 
hyperpigmentation, but includes several other pathologies including IPF, GI 
dysfunction, osteoporosis, cirrhosis, bone marrow failure and increased rates of 
cancer, the last two which are the primary causes of death.  Mutations in several 
different genes cause DC, and most of these lead to decreased levels of 
telomerase function, including TERT, TERC, DKC1, NOP10, NHP2, and TCAB1.   
Recently, mutations in other telomere maintenance factors TINF2, CTC1, and 
RTEL have been found to cause rare cases of DC, and about a third of cases 
remain of unknown genetic origin.  DC is now recognized as part of a spectrum 
of diseases, including the more severe Hoyeraal-Hreiderasson, Coats Plus and 
Revesz syndromes, which are also caused by more severe mutations in some of 
the same genes.  Accordingly, all of these diseases are characterized by 
prematurely shortened telomeres, which appear to be central to pathogenesis.  
There are other progeroid diseases in which telomere maintenance is 
compromised, including Werner syndrome (WS), Hutchinson-Gilford progeria 
syndrome (HGPS), ataxia telangiectasia, Fanconi anemia, Bloom syndrome and 
Rothmund Thompson syndrome.  Each of these is caused by mutations in 
proteins that also have clear effects outside of telomeres, e.g. in each of these 
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diseases, the genome is destabilized globally, and thus it is unclear to what 
extent the telomere defects are the primary drivers of pathology.  WS is caused 
by the loss of the WRN DNA helicase, which is important for efficient 
recombination and DNA replication, including telomere lagging strand synthesis 
(119, 120).  WS is particularly notable for two reasons.  First, among all progeroid 
diseases, its spectrum of pathologies most closely mimics that of natural aging 
(121).  These include atherosclerosis, type II diabetes mellitus, osteoporosis, loss 
of subcutaneous adipose tissue, hair greying, bilateral cataracts, and elevated 
rates of cancer, albeit with some notable differences from natural aging, e.g. the 
osteoporosis affects primarily the limbs rather than axial skeleton, and the cancer 
spectrum is skewed from carcinomas to sarcomas.  Along these lines, it is 
noteworthy that WRN polymorphisms have been associated with longevity (122, 
123).  Second, there is strong evidence that telomere defects in fact make major 
contributions to WS.  Artificial expression of hTERT in cultured WS fibroblasts 
rescues their short telomeres and growth defects, and strongly suppresses the 
elevated rate at which chromosome aberrations are generated, indicating 
chromosome instability is driven by telomere dysfunction (124).  And in mice, the 
naturally high levels of telomerase appear to mask defects that otherwise emerge 
when WRN is lost (125, 126).  Therefore it may be that telomere-related 
degenerative defects in WS are skewed toward those occurring in tissues in 
which telomerase activity is particularly low, e.g. in several mesenchymal tissues, 
which are generally most affected in WS (this excludes bone marrow, where 
telomerase activity is relatively high).  
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 The DC spectrum of diseases have come to be known as “the telomere 
syndromes” or “telomeropathies”, and for good reason, given the clear primary 
role of telomere defects in these diseases and their overlap with telomere-related 
pathologies in “normally” aged individuals such as aplastic anemia or idiopathic 
pulmonary fibrosis.   However, as suggested previously (127), it may be that the 
DC spectrum of diseases reveals primarily how telomere dysfunction affects 
highly proliferative tissues (e.g. bone marrow, GI epithelium, epidermis, or 
tissues that are induced to proliferate by injury, e.g. lung epithelium, liver 
epithelium), whereas WS may provide complementary information on the 
consequences of telomere defects in less proliferative tissues, and thus the full 
spectrum of “telomere syndromes” may be broader than those illustrated by the 
DC-related set of diseases. This idea fits reasonably well with mutations in 
telomerase components being the chief source of DC spectrum diseases, and 
with higher levels of telomerase expression in highly proliferative tissues.  It is not 
yet clear if telomere defects play more important roles in natural aging in tissues 
with low levels of proliferation and telomerase or with high levels of proliferation 
and telomerase.  
MOUSE MODELS OF TELOMERE DYSFUNCTION 
Telomeres in Mice  
Inbred lab mice are the most widely used mammalian models for the study 
of telomerase and telomere biology. Compared with humans, these mice have 
much longer telomeres, higher telomerase activity in somatic tissues, and yet a 
much shorter lifespan. These facts are sometimes used to argue that telomere 
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shortening cannot be a cause of human aging, but this assertion is based on the 
notion that aging mechanisms need to be evolutionarily conserved.  In fact, 
because they are executed primarily after the age of reproduction, pro-aging 
mechanisms are under relatively little selective pressure, and so are more free to 
vary among species (128).   As argued above, humans appear to have evolved a 
strategy that uses telomere shortening to combat cancer, whereas mice have not, 
and so humans may be more subject to the downside of this strategy, i.e. tissue 
homeostasis limited by telomere dysfunction at later ages (129, 130).  Consistent 
with this view, there is no correlation between telomere length and longevity 
among mouse strains. Commonly used strains of inbred lab mice (C57BL/6J, 
FVB/NJ, and 129/SvJ) with long heterogeneous telomere lengths ranging from 
30-150 kb do not live significantly longer than other wild-derived inbred lab mice 
(Mus spretus and Mus musculus castaneus) with shorter telomere lengths (18-20 
kb).  Moreover, the non-Mus wild-derived Peromyscus leucopus mouse has a 
long relative lifespan of 5-7 years compared to that of the inbred lab mouse (~2 
years), yet its average telomere length (~12 kb) is relatively short (131).  Also 
consistent with the view that telomere length is not limiting in inbred lab mice are 
observations that when a core component of telomerase (mTR or mTert) is 
knocked out telomeres shorten, but the first generation (G1) of such mice have 
little apparent phenotypes or pathologies because telomeres apparently do not 
shorten to a critical length (132-135). 
Nonetheless, there is evidence that telomeres may affect cancer and 
aging in normal mice to some degree.  Telomere attrition does occur with age in 
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mice, and even though only to mean lengths that are longer than dysfunctional 
human telomeres, one cannot rule out the possibility that critically shortened 
telomeres may be present (136).   Indeed, TIFs increase in frequency with age in 
mice - and caloric restriction, which delays aging, delays telomere shortening 
(69, 137).  Furthermore, overexpression of telomerase causes elevated rates of 
cancer in mice, but in mice protected from cancer by additional copies of p53 and 
p16/Arf, the extra telomerase extended median (but not maximum) lifespan 
approximately 15% and delayed age-related pathologies (138).  To the extent 
that telomeres play more limiting roles in humans than in mice, one would expect 
that strategies to improve telomere maintenance would have much larger effects 
in humans.  These effects might be beneficial, as well as deleterious (e.g. via 
promoting cancer). 
Mouse models of telomere dysfunction 
Telomerase deficient mice have helped us understand the consequences 
of critical telomere shortening (132-135). Since there is no telomerase in the 
germ line of telomerase knockout mice, they pass on shorter telomeres to their 
offspring, although it is an open question as to what extent ALT activity during 
development – particularly prior to the blastocyst stage – might counter critical 
shortening (139).  Regardless, after several generations of breeding, 
successively shorter telomeres are passed down to the next generation.  
Eventually, once telomeres have shortened to a critical length, pathologies 
associated with dysfunctional telomeres become apparent. How many 
generations must elapse before telomerase deficiency manifests its effects 
23	  
depends on the starting telomere length.  In the CAST/Eij mouse model where 
the starting telomere length is comparable to humans, telomerase 
haploinsufficiency (mTR+/- or mTert+/-) is enough to critically shorten telomeres, 
similar to DC patients who are haploinsufficient for telomerase (140, 141). In 
C57Bl/6 mice, which have longer telomeres than CAST/Eij mice (142), mTR-/- 
deficiency by later generations (G4-G6) leads to decreased lifespan and signs of 
premature aging and decreased somatic and germ cell replicative capacities, 
characterized by apoptosis and growth arrest, particularly in high turnover 
tissues, similar to pathology in DC. Deletion of shelterin proteins in mice has also 
informed us of the function of these proteins in mouse telomere biology. Trf1, 
Trf2, Tpp1, Pot1a, and Tin2 deletion result in embryonic lethality, while Rap1 and 
Pot1b knockout mice survive to adulthood and have no apparent phenotypes 
(143-148). Knocking out Trf1 and Trf2 in cells rapidly induces end-to-end 
chromosome fusions and cellular senescence. As mentioned earlier, late-
generation mTR-/- mice have a phenotype that is characterized by decreased 
proliferation capacity in organs with high tissue turnover rates. Intestinal atrophy, 
infertility, poor wound healing, alopecia and greying of the fur, neural tube 
closure defects, bone marrow aplasia, cardiac dysfunction, and runting are some 
of the degenerative features of the mTR-/- mice (149, 150).  
Dysfunctional telomeres are recognized as double stranded DNA breaks 
and set off DNA damage responses (20). First, the MRN (Mre11-Rad50-Nbs1) 
complex recognizes double stranded DNA breaks and recruits ATM to the site of 
damage. Following auto-phosphorylation and thus activation, ATM 
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phosphorylates key proteins to activate the DNA damage checkpoint, leading to 
DNA repair, cell cycle arrest, or apoptosis. CHK2, H2AX, and p53 are some of 
the DNA damage proteins that ATM directly phosphorylates and activates. 
Uncapped telomeres results in the activation of p53, a tumor suppressor gene 
that can initiate apoptosis or cell cycle arrest and activate DNA repair proteins. 
Activated p53 can act as a transcription factor and can activate expression of 
several genes such as microRNA-34a (miR-34a), CDKN1a (i.e. p21), PUMA, and 
SIAH1 (151).  
p53 conducts many of the downstream effects seen with uncapped 
telomeres. Deletion of p53 in different contexts of telomere dysfunction (caused 
by critical telomere shortening or telomere uncapping from shelterin defects) is 
able to rescue many aspects of the pathology, such as cell cycle arrest, 
apoptosis, and stem cell function. For example, mice lacking Trf1 in the stratified 
epithelium die perinatally but survive to adulthood when p53 is deleted (152). 
Similarly, p53 deletion rescues many aspects of stem cell dysfunction in late-
generation mTR-/-  mice (which we will discuss in more detail later) (153-156). 
However, deletion of p53 leads to unchecked cell cycle progression in these cells, 
which allows the cells to further accumulate genomic instability, resulting in end-
to-end chromosome fusions and breakage-fusion-bridge cycles during mitosis. 
This sets the stage for the cell to turn into cancer through genomic deletions, 
duplications, and rearrangements. Indeed, rates of cancer are increased in mice 
lacking p53 and mTR or Trf1 in stratified epithelium.  
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Conversely, telomere dysfunction with an intact p53 response exerts a 
tumor suppressive effect, as mTR-/- mice have reduced incidences of cancer, and 
delays cancer onset in the cancer-prone Ink4a/Arf-/- mice (157). Telomere 
dysfunction can be thought of a driver for genomic instability, and may actually 
increase cancer initiation (e.g. late-generation mTR-/-APC+/min mice increases 
numbers of early-stage microadenomas), but decrease cancer progression – 
telomere shortening in the absence of telomerase but in the presence of 
functional p53 can inhibit malignant cell division (e.g. late-generation mTR-/-
APC+/min mice have decreased numbers of late-stage macroadenomas) (158, 
159). 
Cell senescence or apoptosis caused by telomere uncapping has been 
thought to be cell autonomous. Thus, genetic inactivation of factors that minimize 
telomere degradation (Exo1) or responses to uncapped telomeres (p53, p21, or 
PUMA) has been found to be of benefit in mice lacking telomerase (156, 160-
162).  But the recent demonstration that cell senescence can be propagated in 
an intercellular fashion (80) raises the possibility that non-cell autonomous 
mechanisms might impact pathology caused by telomere uncapping. 
WNT SIGNALING, INTESTINAL STEM CELLS, AND TELOMERES 
Wnt Pathway 
The Wnt pathway was initially discovered in Drosophila when the Wingless (Wg) 
gene was mutated to cause wingless fruitflies (163). Wg had a high degree of 
conservation across species, including the Int-1 (integration) oncogene in mice 
(now known as Wnt1), discovered as a site of frequent retroviral integration by 
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the mouse mammary tumor virus (MMTV), which causes mammary tumors in 
mice (164). The Wg gene is important for segment polarity during embryonic 
development. The Wg/Int pathway was eventually renamed as Wnt, to reflect 
both origins of discovery.  
The Wnt signaling pathways are a group of highly conserved signal 
transduction pathways that can be classified into two main categories: the 
canonical Wnt pathway and the noncanonical Wnt pathway. Both the canonical 
and the noncanonical pathways are activated by extracellular Wnt protein ligands 
that bind to specific cell surface receptors (Frizzled receptors, Fzd) to activate 
downstream intracellular signals through the Dishevelled protein. The canonical 
Wnt pathway leads to an accumulation of β-catenin to regulate gene expression, 
while the noncanonical pathways operate independently of β-catenin. The 
noncanonical Wnt pathway has been described to be involved in planar cell 
polarity (165, 166). 
The canonical Wnt pathway is initiated when extracellular Wnt ligand 
proteins bind to the Fzd, LRP5/6 cell surface protein receptors, which activate the 
intracellular Dsh protein. Activated Dsh inhibits the GSK3/Axin/APC destruction 
complex, which sequesters β-catenin in the cytoplasm and targets it for 
ubiquitination and subsequent degradation. Once the destruction complex is 
inhibited, levels of β-catenin build up in the cytoplasm and localize to the nucleus. 
In the nucleus, β-catenin binds to the TCF/LEF transcription factors to initiate 
gene expression changes. There are other players involved in the Wnt pathway, 
including other ligands and receptors. R-spondin proteins are a family of proteins 
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that are secreted and can activate the canonical Wnt pathway via the Lgr family 
of receptors, Lgr4/5/6 (167, 168). R-spondin proteins may also bind to and inhibit 
the ZNRF3 and RNF43 transmembrane molecules, which are Wnt target genes 
but also negatively feedback on Wnt signaling by increasing turnover of the Fzd 
receptors (169). Similarly, Ror proteins are a family of tyrosine kinase receptors 
that can modulate Wnt signaling depending on the cell type, and they may 
sequester Wnt ligands to prevent them from binding to Fzd receptors. Ryk is 
another family of tyrosine kinase receptors that can activate the canonical Wnt 
pathway through Dsh. It has long been thought that specific Wnt ligands activate 
different Wnt pathways (e.g., Wnt 11 activates the noncanonical Wnt pathway), 
but it is now thought that the signaling outcome is dependent on the combination 
of receptors activated (170). 
There are several inhibitors of the canonical Wnt pathway, including Wnt 
inhibitory factor-1 (Wif-1), Dickkopf (Dkk), Cerberus, Wise, SOST, Frzb, and the 
soluble frizzled proteins (Sfrps). There are also cytosolic inhibitors of Wnt 
signaling, including Axin2 and Nkd, which are both Wnt targets and negatively 
feedback on the pathway. Wnt ligand diffusion may be inhibited through 
interactions with Dally and glypican 3. Dkk (forms 1-4) can bind to LRP and 
Kremen, which may downregulate LRP from the cell surface. Sfrps are secreted 
proteins that mimic Fzd proteins (without transmembrane domains) and can 
sequester Wnt ligands. Similarly, Wif1 also binds Wnt ligands to prevent them 
from binding to Wnt receptors (171). 
Wnt Signaling in Intestinal Stem Cell Homeostasis 
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The canonical Wnt pathway is important for the embryonic development of the 
gastrointestinal tract and the maintenance of intestinal stem cell (ISC) 
homeostasis (172). Mutation of genes involved in canonical Wnt signaling can 
disrupt the development of the GI tract and can also initiate tumors. When Tcf1 
(also known as Tcf7) and Tcf4, transcription factors of canonical Wnt signaling, 
are both knocked out in mice, severe hindgut and gastrointestinal defects are 
present (173). Inactivating mutations of APC can lead to unchecked Wnt 
signaling and intestinal adenomas and cancer in mice and humans (158). Wnt 
signaling is also important for maintaining the ISC niche environment in adult 
intestinal crypts. 
The normal maintenance of mammalian intestinal epithelium involves 
remarkably high rates of cell turnover.  For example, the small intestinal 
epithelium of mice is replaced every 3-5 days (174, 175).  Fundamental to this 
homeostasis are the activities of intestinal stem cells (ISCs), which reside within 
the deepest recesses of the intestinal epithelium at the base of each crypt.  ISCs 
include both so-called crypt base columnar cells (CBCs) and label-retaining cells 
(LRCs).  CBCs divide on a daily basis (176) and are located at the base of crypts 
where they are intercalated between Paneth cells, which along with underlying 
stromal cells contribute to the CBC niche.  Importantly, both Paneth and stromal 
cells provide intercellular Wnt signals (e.g. Wnt3 from Paneth cells) to support 
the CBC niche (177).  In contrast, LRCs divide infrequently, are located above 
Paneth cells at approximately the +4 position, and are independent of Wnt 
signals (178). Both CBCs and LRCs produce progeny that can differentiate into 
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all intestinal epithelial cell types, and it is thought that CBCs typically serve this 
function, whereas LRCs divide to replace CBCs on the occasion of their loss. 
The crypt niche environment is composed of ISCs and Paneth cells, which 
produce bactericidal enzymes but also secrete EGF, the Notch ligand Dll4, and 
multiple Wnt ligands, Wnt11 and Wnt3 (177). Wnt3 is an important Wnt ligand for 
ISC maintenance, and Paneth cells are the sole source of Wnt3 production in the 
crypt epithelium. The underlying stroma is also an important source of Wnts and 
can compensate for loss of Wnts from Paneth cells (179). Wnt3 is not essential 
for ISC maintenance in vivo because stromal sources of Wnt (e.g. Wnt2B) can 
compensate, but ex vivo cultures of intestinal organoids, without the presence of 
stromal cells, Wnt3 and Paneth cells are essential for organoid and ISC survival 
(179). Wnt3 can substitute for R-spondin1 or other Wnt-activating agents, such 
as CHIR99021 (an inhibitor of GSK3) in ex vivo intestinal organoid cultures. The 
standard recommended ex vivo/in vitro organoid culture system is supplemented 
with the growth factors EGF, Noggin, and R-spondin1 (180).  
Wnt and Aging 
Wnt signaling is important in development and cancers, and recent reports 
suggest Wnt signaling is also important in replicative senescence and aging, 
although many studies report contradictory roles for Wnt signaling. The 
discrepancies between the studies have yet to be resolved, since it is context-
dependent and also depends on the models/tissues/cells used. WI-38 cells 
undergoing replicative senescence or oncogenic-activated senescence have 
decreased Wnt2 ligand expression, and knockdown of Wnt2 was sufficient to 
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induce premature senescence (181). Exogenous Wnt3a delayed oncogene-
induced senescence in one setting, but in another study, increased Wnt signaling 
activity in the Klotho mouse model accelerated cell senescence and aging (182). 
The Klotho protein has many functions, one of which is to sequester Wnt3 and 
inhibit it from activating the Wnt pathway. Impairment in Klotho gene expression 
increases Wnt pathway activity, and also decreases stem cells in the skin and 
intestine (182). However, Klotho also inhibits the insulin/IGF pathway, which has 
also been implicated in aging and stem cell biology, and can affect additional 
pathways and so the role of Wnt signaling in these experiments is unclear. 
Another study saw an increase Wnt pathway activity in mesenchymal stem cells 
incubated with aged rat serum and inhibition of Wnt signaling promoted 
proliferation (183). Skeletal muscles have also been observed to convert from a 
myogenic to a fibrogenic lineage and found to have increased Wnt signaling 
when incubated with aged serum, and muscle regeneration in aged mice was 
enhanced by the inhibition of Wnt signaling (184). However, Wnt signaling is 
typically mediated in a short-range paracrine fashion, and pro-Wnt factors in the 
serum may be different from short-acting Wnt ligands. Differences in the above 
conflicting reports may also be explained in part by the pleotropic and tissue-
specific effects of Wnt signaling. As mentioned earlier, the combination of Wnt 
receptors that are activated on the cell surface can result in very different 
downstream consequences, and the timing and duration of the signals can have 
opposite effects. For example, even though Wnt signaling promotes 
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hematopoietic stem cell proliferation, constitutive Wnt activation can drive 
hematopoietic stem cell exhaustion (185-188).  
Wnt and Telomeres 
Telomerase and Wnt signaling play important roles in the regulation of cancer, 
aging, and stem cell biology, and many studies explore their relationship with 
each other. TERT has been shown in several systems to be a target gene of the 
canonical Wnt pathway, and other studies have also proposed that TERT acts as 
a transcription factor within the canonical Wnt pathway, although discrepancies 
exist which question the validity and the physiologic relevance of the latter model. 
We will go into a brief overview of the studies that describe these connections, 
the discrepancies, and their relevance to this thesis.  
TERT is a direct and canonical Wnt target gene in normal and cancer cells 
of humans and mice through the binding of β-catenin directly to the TERT 
promoter. Activation of Wnt signaling by LiCl (which inhibits GSK3, among other 
activities), Wnt3a-conditioned medium, or overexpression of constitutively active 
β-catenin induced hTERT expression and telomerase activity in multiple human 
cell lines, through TCF4-mediated transcription. Inhibition of β-catenin expression 
reduced hTERT expression, telomerase activity, and increased rates of telomere 
shortening (189). Similar results were found in a separate study looking at mouse 
embryonic stem cells, mouse intestinal cancers caused by overactive Wnt 
signaling and human cancer cell lines, mediated by β-catenin and KLF4 binding 
at the Tert promoter (190). These observations are in addition to what is already 
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known about the regulation of TERT transcription through the c-Myc transcription 
factor, which itself can be regulated by β-catenin/Wnt signaling. 
Many investigators have studied the overexpression of TERT in human 
and mouse systems, and many have observed non-telomere lengthening effects 
of telomerase, including the inhibition of apoptosis and promotion of cell division. 
TERT overexpression in mouse skin induced robust follicular bulge stem cell 
proliferation that resulted in robust hair growth, which was still the case even 
when telomerase-lengthening effects were abolished (i.e. in mice lacking mTR or 
when a catalytically-inactive form of TERT was overexpressed)(191, 192). The 
authors identified changes in gene expression regulated by the Myc and Wnt 
pathways when TERT expression was switched off (192). Follow-up studies by 
the group identified direct association of endogenously FLAG-tagged mTERT 
with β-catenin and BRG1, a chromatin remodeling factor shown to promote β-
catenin target gene expression (99).  The authors also describe mild homeotic 
transformations in first-generation mTERT-/- mice (before telomeres are critically 
short), characterized by loss of the 13th rib on one or both sides in 6 out of 13 
mice. Multiple groups have attempted to replicate these results, but to date, there 
have been no success yet. Moreover, it would be expected that extra-telomeric 
functions of TERT would manifest in phenotypes of mTERT-/- mice that are 
different from mTR-/- mice. This was investigated through comparisons of several 
models – livers from mTERT-/- and mTR-/- mice, mouse embryonic fibroblasts 
(MEFs) from mTERT-/- and wild-type littermates produced from heterozygous 
mTERT+/- parents, and comparisons between mTERT-/- and mTR-/- mice on a 
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different strain background – but there was lack of evidence for any gene 
expression or phenotypic differences between mTERT-/- and mTR-/- (140, 193).  
Many have also raised the question of physiologic relevance in an 
overexpression system, where TERT could have gain-of-function phenotypes. 
TERT overexpression in several human cell lines was also contributed to the 
increase in Wnt reporter activation (99, 194). However, in hepatocellular 
carcinomas with mutations in the promoter-region of hTERT (which increases 
TERT expression), there was no activation of the Wnt pathway (195). 
Futhermore, hTERT overexpression failed to activate Wnt signaling in various 
cancer cells, including some of the same cells from previous studies (101). The 
authors postulate that the discrepancies are due to differences in cell types and 
the numbers of TCF/LEF sites in the reporters used. Surprisingly, they also failed 
to detect interaction between FLAG-hTERT and endogenous BRG1 or between 
BRG1 and β-catenin. However, they detected interaction between non-affinity-
purified anti-FLAG M2 antibody and β-catenin antibody, which raises the 
possibility that previous reports were detecting artifact from antibody cross-
reactivity.  
Another connection exists between Wnt and telomeres through the 
regulation of TRF2 expression by the Wnt pathway. TRF2 expression was 
described to be highly upregulated in human hepatocellular carcinomas with 
activating mutations in β-catenin and similarly in mouse intestines with increased 
Wnt signaling activity from mutations in APC (196). The TRF2 gene was 
discovered to contain TCF-LEF transcription binding sites, where β-catenin was 
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also found to bind. Furthermore, when β-catenin was knocked down by siRNA 
approach, there was a marked decrease in TRF2 and telomere dysfunction, 
which was rescued by TRF2 overexpression. Depletion of TRF2 or disruption of 
TRF2 function in mice and in human cells (through knock-out models or 
overexpression of a dominant negative form of TRF2, respectively) has been 
shown to be deleterious, causing rapid telomere uncapping, loss of 3’ G-rich 
overhangs, resulting in non-homologous end joining of chromosome ends (143, 
197). In this thesis, I describe functional connections between telomeres and the 
Wnt pathway that align most closely with this last set of observations, i.e. a role 
for Wnt signaling in promoting expression of TRF2 and thus telomere capping.  
And furthermore, I present novel evidence that the regulation runs in the reverse 
direction as well, with telomere capping helping to support active Wnt signaling, 
thus describing a positive feedback loop between telomere capping and Wnt 
pathway activity. 
 
MICRORNAS 
Introduction to microRNAs  
 Less than 2% of the transcribed human genome codes for proteins. Non-
coding RNAs (ncRNAs) are divided into two simple classes based on nucleotide 
length: long ncRNAs (lncRNAs) of transcripts longer than 200 nucleotides, and 
small ncRNAs less than 200 nucleotides in length. Among the small ncRNAs are 
microRNAs, Piwi-interacting RNAs, small nucleolar RNAs, tRNAs, short 
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interfering RNAs, and other RNAs. Of particular interest to this thesis is 
microRNAs, which are highly conserved across species and are important for the 
regulation of gene expression (198, 199). 
Functional mature microRNAs are 18-25 nucleotide small RNAs that 
target specific and unique mRNAs for degradation or to inhibit mRNA translation. 
microRNAs are encoded by their own genes or from introns or exons (200). They 
are transcribed in the nucleus by RNA polymerase II or III into primary-
microRNAs (pri-miRNAs), which are capped at the 5’ end, and polyadenylated 
and spliced. Drosha (a ribonuclease) and DGCR8 (an RNA-binding protein) 
cleave the pri-miRNAs into the hairpin precursor miRNAs (pre-miRNAs), which 
are shuttled out of the nucleus by Exportin-5. In the cytoplasm, the RNAse Dicer, 
along with TRBP (a double-stranded RNA-binding protein), cleaves the loop from 
pre-miRNAs into a resulting 3’ and 5’ arm duplex, yielding the mature microRNA 
duplex (201, 202). The miRNA duplex contains a guide strand, which is ultimately 
loaded onto the RNA-induced silencing complex (RISC) with Argonaute (Ago2) 
proteins to direct the functional output of the miRNA, along with an imperfectly-
complementary passenger strand (miRNA*), which is typically targeted for 
degradation (203, 204). When one arm of the duplex is found in much higher 
amounts and is the predominant guide strand, the asterisk indicates the mature 
miRNA on the other, less functional, arm (198). However, since in some cases, 
either the 5’ or the 3’ arm of the miRNA duplex (termed miRNA-5p or miRNA-3p, 
respectively) can act as a guide strand, depending on the cell type and the 
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condition, the -5p or -3p designation is becoming the preferred suffix over the 
asterisk. 
An introduction of miRNAs is not complete without an overview of 
microRNA nomenclature. MIR refers to the gene encoding the microRNA (e.g. 
MIR-145) and uncapitalized “mir-“ refers to the pri-miRNA and pre-miRNA (e.g. 
mir-145), while the capitalized “miR-“ refers to the mature miRNA (miR-145). 
miRNAs with 1 or 2 nucleotide differences are annotated with a lower case letter 
(e.g. the sequence of miR-34a is similar to miR-34b and miR-34c, and they are 
all encoded by different genes). When different genes, pri-miRNAs or pre-
miRNAs encode for identical mature miRNA sequences, they are annotated with 
a dash-number suffix (e.g. pre-miRNAs hsa-mir-194-1 and hsa-mir-194-2 both 
encode for hsa-miR-194). The species of origin is designated by a 3-letter prefix 
(e.g. mmu-miR-34a is from Mus musculus and hsa-miR-34a is from Homo 
sapiens) (205).  
Only one strand of the miRNA duplex is generally loaded onto RISC, and 
selection of the guide strand is based on the thermodynamic stability of the 5’ 
ends. Generally, the strand with the less stable 5’ pairing to its complement is 
incorporated into RISC as the guide (206, 207). Argonaute proteins are important 
for the function of RISC. They directly bind to the mature miRNA with two RNA-
binding domains: the PAZ domain that binds the 3’ end and the PIWI domain that 
binds the 5’ end of the mature miRNA (208). Argonaute proteins may directly 
cleave target mRNA transcripts with its endonuclease activity or recruit proteins 
that will inhibit mRNA translation. In humans, there are two families of Argonaute 
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proteins, the Ago subfamily (ubiquitously expressed in all mammalian cells) and 
the Piwi subfamily (expressed in germ cells and hematopoietic stem cells). Ago 
proteins associate with miRNAs and siRNAs while Piwi proteins associate with 
piRNAs. Perfect complementarity of miRNAs and target mRNA promotes Ago-
mediated degradation of the mRNA, whereas partial complementarity promotes 
inhibition of mRNA translation or deadenylation (209).  
Only ~seven nucleotides of the mature miRNA are required to have 
complementarity in order to recognize its target, and this is known as the seed 
region (210). The seed region is at nucleotide positions 2-7 of the mature miRNA, 
and mutations in the sequence has been attributed to several genetic disorders . 
Several other features also promote specificity of miRNA recognition to target 
mRNA (211). A single miRNA can have hundreds of target mRNAs. Attempts to 
identify miRNA targets include computational approaches to predict mRNA 
targets based on sequence complementarity, which can result in thousands of 
predicted targets for a single miRNA, and follow-up functional biological 
experiments to confirm target specificity is required but can be tedious. HITS-
CLIP (high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation) of Argonaute proteins have been able to identify mRNA 
targets of miRNAs (212).  
microRNAs in Aging and Disease 
Even though the field of non-coding RNAs is relatively new – with the 
initial discovery of the miRNA, lin-4, in C. elegans in 1993 (213), followed by the 
discovery of let-7 in 2000 (214) – it is now widely recognized that miRNAs play 
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important roles in development, aging, and disease. miRNAs fine tunes and does 
not completely turn off gene expression, and they have been shown to affect 
gene expression by only 1.2 to 4-fold (215). New miRNAs are still being 
discovered (approximately 500-1000 have been found by RNA-seq), and we 
have only begun to scratch the surface in revealing what regulates them and 
what their functions are. There is a huge need but a lack of a high-throughput 
approach to evaluate the functional role of miRNAs. Currently, the most common 
approaches to evaluate miRNA changes is with miRNA microarrays, and in silico 
analyses are used to predict mRNAs targeted by miRNAs, confirmed by 
functional studies overexpressing, knocking-out, or knocking-down specific 
miRNAs knocking-down miRNAs.  
The profile of miRNAs during aging and senescence is still relatively 
obscure but of great interest, and several investigators have begun to 
characterize them. There are common miRNAs that are upregulated and 
downregulated in different tissues and conditions of aging. In a number of in vitro 
and in vivo studies across species and tissues, the most commonly and 
consistently upregulated miRNA with age is miR-34a (216-220). Overexpression 
of miR-34a has contributed to accelerated senescence and cell cycle arrest in 
multiple cell lines (221-226). Furthermore, miR-34a has been found to play a 
significant role in aging and the lifespan of C. elegans, and loss of function of 
miR-34a delays age-related pathology, reduces oxidative stress and extends 
lifespan (227). Other notable miRNAs that are upregulated with aging are miR-
181, miR146a, miR-195, the miR-200 family members, among others (228, 229). 
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There are also miRNAs that are consistently downregulated with aging from C. 
elegans to multiple human cell types, such as the miR-17-92 cluster, which 
encode for six mature miRNAs, one of which (miR-19) targets PTEN and 
activates the AKT/mTOR pathway, a key pathway involved in lifespan regulation. 
The paralogous clusters of miR-17-92, which are miR-106a-366 and miR-106b-
25, are also downregulated in replicatively senescent cells and aged human 
tissues (230, 231). Many of the miRNAs upregulated in aging are also involved in 
inflammatory processes and cancers, such as miR-146a and miR-181 family 
members (215). It is interesting to note that the same miRNA can be upregulated 
in some cancers and downregulated in other cancers (e.g. miR-181 family 
members are upregulated in breast and colorectal cancer but downregulated in 
glioblastomas and prostate cancer) (232-235). 
In summary, telomeres are important for genome stability, cancer and 
aging, and we do not yet fully comprehend their roles nor the underlying 
mechanisms.  We have found evidence for a positive feedback loop between 
telomere capping and Wnt pathway activity in the small intestinal stem cell niche, 
which can also be described as a circuit in which telomere uncapping drives 
downregulation of the Wnt pathway.  Consistent with this idea, and the 
established role for p53 in mediating DDRs in response to uncapped telomeres, 
we have found some evidence that the p53-regulated microRNA miR-34a plays 
roles in downregulating the Wnt pathway in this setting. 
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CHAPTER 2: GENERAL METHODS 
Study Design 
Histologic comparisons of WT, G2, and G4 mTR-/- mice were made between 
groups each having similar average age, and all mice were younger than 12 
months. RNA samples for microarray analysis and qRT-PCR validation were 
obtained from WT and G4 mTR-/- mice aged 7-8 months. For each of the lithium 
and Rspo1 treatment experiments, littermates were divided equally into the 
control and treatment groups.  Comparisons were made between littermates to 
minimize differences in inherited telomere lengths. For cultured crypts 
experiments, G4 mTR-/- mice aged 3 months or younger were used because 
survival of crypts dropped precipitously beyond this age.  
Mice 
All mice were on the C57BL/6J background, and mTR+/- mice were crossed to 
generate G1 mTR-/- mice, which were crossed to generate G2 mice, and so forth 
(135).  A male miR-34a-/- breeder was initially obtained from Jackson 
Laboratories and crossed with mTR-/- mice. All studies were approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee 
(IACUC). The mice were housed in a standard animal care room with 12:12-h 
light-dark cycle with free access to food and water. For lithium treatment, mice 
were given an ad libitum lithium-chow diet of 0.212% lithium chloride-
supplemented chow (Harlan Teklad, Madison, WI) for 3 days, followed by 0.4% 
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lithium chloride-supplemented chow for 7 days. Lithium chow-fed mice were 
given a supplemental source of drinking water containing 1.5% (w/v) sodium 
chloride to counteract potential toxicities of lithium. For Rspo1 experiments, mice 
are injected at 4 µg Rspo1 (in PBS, or PBS alone for controls) per gram body 
weight subcutaneously daily for 8 days. RSpo1 was expressed and purified as 
described (236). 
Cell lines 
Primary human fibroblasts were obtained from the Coriell Institute. The two 
dyskeratosis congenita (DC) lines were: GM01774 (population doubling level 
(PD) 25; from 7 year-old male), and AG04646 (PD 21; from 11 year-old male). 
The three healthy control (WT) lines were: GM01786 (PD 25; 30-year old mother 
of GM01774), GM00409 (PD ~16; from 7 year-old male), and GM00323 (PD 
23.6; from 11 year-old male).  The Werner syndrome line was AG05229B (PD 
~30; from 25 year-old male), which was retrovirally transduced with pBABE-puro-
hTERT, or with the empty pBABE-puro vector as a control. Fibroblasts were 
cultured in DMEM with 15% FBS, with 1X penicillin/streptomycin/amphotericin-B 
at 37oC in a 6% C02 and 3% O2 atmosphere. 
Tissue histology 
Standard five-micron sections were cut from formalin-fixed and paraffin-
embedded samples.  In situ hybridization for Ascl2 was as described (237), and 
immunostaining for Sox9 and for Ki67 used Millipore AB5535 and Abcam 
Ab16667 antibodies, respectively.  TUNEL assays were performed using the 
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ApopTag Peroxidase In Situ apoptosis Detection Kit (Chemicon).  Images within 
each set of staining were taken with identical settings on a Nikon Eclipse E600 
microscope. Brightness and contrast were adjusted post-capture in a linear and 
equal fashion for all samples.  120 crypts per mouse from hematoxylin and eosin 
(H&E) stained sections were surveyed for the presence of anaphase bridges.  
Isolation of intestinal crypt and stromal cells for microarrays 
8 cm of ileum was longitudinally cut and rinsed in cold PBS, followed by firm 
scraping of intestinal villi with hemacytometer coverslip, incubation in 10 ml 30 
mM EDTA and 1.5 mM DTT in PBS on ice for 20 minutes. The intestine was 
transferred to 10 ml 30 mM EDTA in PBS at 37°C for 8 minutes, followed by 3 
rounds of shaking per second for 30-40 seconds. The supernatant was 
centrifuged at 200 g for 1 minute at 4°C, followed by passage through a 70 µm 
cell strainer. The strained supernatant was spun down again at 130 g for 1 
minute at 4°C to deplete single cells, and the crypt pellet was collected for RNA 
extraction. The remaining intestinal tissue is scraped with a coverslip to remove 
residual epithelial cells and is mechanically homogenized with a TissueRuptor 
(Qiagen) before RNA extraction.  
Crypt culture 
Intestinal crypts used for culturing were isolated from the proximal half of the 
small intestine as described (180), except that the intestinal fragments were 
incubated with 30 mL of 30 mM EDTA in PBS for 15 minutes on ice, with 
occasional inversion.  Isolated crypts were cultured in Matrigel (BD Biosciences) 
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with advanced DMEM/F12 medium containing final and basal concentrations of 
100 ng/mL noggin, 50 ng/mL mEGF, and 1 µg/mL RSpo1 (higher levels of 
RSpo1 were used for some experiments as indicated). Approximately 500 
crypts/50 µL of Matrigel were plated per well in a pre-warmed 24-well plate and 
cultured at 37oC in a 6% CO2 incubator with ambient O2. CHIR99021 (Tocris 
Biosciences) was prepared as a 2 mM stock solution in DMSO. 
RNA extraction  
All RNA extractions were performed with the miRNeasy Kit (Qiagen). RNA 
quantity and quality were confirmed with Nanodrop spectrophotometry or Agilent 
Bioanalyzer 2100 with either the Agilent RNA 6000 Nano or Pico kits. 
Quantitative RT–PCR 
Reverse transcription was performed with miScript II RT Kit (Qiagen) according 
to the manufacturer, using miScript HiFlex buffer. This allows for the qRT-PCR 
analysis of both microRNAs and mRNAs. The ability of the miScript II RT Kit to 
detect mRNAs was confirmed by simultaneous reverse transcription reactions 
with MultiScribe Reverse Transcriptase (Life Technologies). Real-time PCR was 
performed on a Roche LightCycler 480 using SYBR Green JumpStart Taq 
ReadyMix (Sigma). Reactions (10 mL) were performed in triplicate, as follows: 10 
minutes at 950C, 45 cycles of 15s at C95oC, 30s at 59oC, 30s at 72oC. Melt curve 
and gel electrophoretic analyses were performed to verify specific target 
amplification. Amplification from experimental samples was normalized to 
standard curves that were made from dilutions of pooled samples. Cp values 
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from each amplification curve were computed by the second-derivative method, 
the mRNA expression levels were normalized to that of β-actin, and the mature 
miRNA expression levels were normalized to that of RNU6. Primer sequences 
are provided in the Tables section.  Student’s t-tests were used for comparisons, 
except that a 2-way ANOVA (multiple comparisons) was used for statistical 
analyses of human fibroblasts, comparing the gene expression at each dose of 
CHIR99021 to no drug within each genotype. 
Statistics 
p-values were calculated with Prism. Unpaired t-tests assuming equal population 
SD were performed unless specified.  
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CHAPTER 3: WNT-SPECIFIC ISC MARKERS ARE DOWNREGULATED IN 
MICE WITH DYSFUNCTIONAL TELOMERES WITHOUT APPARENT LOSS 
OF CBCS 
INTRODUCTION 
 Stem cells of the GI tract are located in specific regions: the crypt base of 
the small intestine, the mid-crypt of the ascending colon, and the crypt base of 
the descending colon (238). Characterization of intestinal stem cells in mTR-/- 
mice has mostly been described in the small intestine despite pathology existing 
in the colon as well, most likely because murine models of intestinal cancers 
have the most pronounced phenotype in the small intestines (in contrast to 
human intestinal cancers, which are predominantly in the colon) (239). We also 
focus our studies on the small intestine of mTR-/- mice. The small intestine is 
divided into 3 different parts, the duodenum, jejunum, and ileum, and these 
distinctive parts are difficult to distinguish grossly in mice, although their location 
along the small intestine roughly corresponds to thirds by length (i.e. duodenum 
makes up the first third of the small intestine, and so on). The small intestinal 
epithelium is composed of villi that project into the lumen and intestinal crypt 
invaginations. There exists a crypt-villus axis that reflects the differentiation state 
of the cells. There also exists a gradient of decreasing Wnt signals and 
increasing BMP signals along the crypt-villus axis, which has been suggested to 
contribute to the stemness/differentiation state of cells along the axis (172). Each 
crypt comprises approximately 250 cells, containing ISCs and Paneth cells at or 
near the crypt base (240). Each crypt of the small intestine has a remarkable 
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capacity to divide and give rise to cells that differentiate into several lineages that 
contribute to the epithelium of 2-3 villi. ISCs give rise to rapidly-cycling progenitor 
cells called transit-amplifying (TA) cells, which differentiate terminally into 
absorptive enterocytes, goblet cells, Paneth cells, enteroendocrine cells, and 
other cells. In the mouse small intestine, the movement of cells is from the base 
of the crypt to the villus tip except for Paneth cells, which are anchored at the 
base of the crypt . The small intestinal epithelium in mice turns over 
approximately every 3-5 days, and epithelial cells are shed from villus tips into 
the lumen (241).  
 As mentioned briefly in the introduction, two types of ISCs exist, the fast-
cycling CBCs at the base of the crypt and the slow-cycling LRCs at the +4 to +7 
position from the base of the crypt (they have also been called +4 LRCs). There 
is an estimated number of 15 CBCs per crypt (242). It has been suggested that 
LRCs serve as a stem cell reserve pool, and can divide into CBCs to replace 
damaged/dying CBCs (178, 243). There is also evidence that CBCs have the 
potential to convert into LRCs (244). Both CBCs and LRCs share some common 
stem cell markers, but they are also driven by different signals (e.g. CBCs are 
driven predominantly by Wnt signaling) and have distinct stem cell signatures 
(241). There is no consensus in regards to what markers define the putative stem 
cell populations, as there is some controversy in how some have determined the 
stem cell signature (i.e. based on their position within the crypt, or lineage tracing, 
etc.) (241). However, there is agreement that Lgr5 is a specific CBC marker, and 
that is both a direct Wnt target gene and is itself a Wnt receptor at the cell 
47	  
membrane (245-247). Gene expression analysis of Lgr5-EGFP crypt cells has 
determined a signature of CBCs, and identifies Ascl2 (another Wnt target gene) 
and Olfm4, an indirect Wnt target gene (itself a target gene of Ascl2), as robust 
CBC markers (237, 245). Visualization of single mRNA transcripts by in situ 
hybridization confirmed that Lgr5 and Ascl2 are exclusively expressed in CBCs, 
while Olfm4 and Musashi-1 (Msi1) have a broader expression, with Msi1 
extending into the TA cells (248, 249). Many +4 LRC markers have been 
proposed, with Bmi1 being the first marker that was described. Bmi1+ cells are 
distinct from Lgr5 cells, are relatively quiescent, and are independent of Wnt 
signaling. HopX, mTert, Lrig1, and many other genes have been described to 
mark +4 LRCs, but there is a lot of evidence that suggest their broad expression 
in other cell types (241, 249). For example, Lgr5+ cells have the highest levels of 
endogenous telomerase activity in the crypt (250). 
Intestinal stem cell (ISC) exhaustion has been hypothesized to underlie 
compromised epithelial integrity in late-generation telomerase-deficient mice. We 
therefore investigated ISC marker gene expression in these mice. Further, as 
mentioned in the introduction, because the TERT protein has been suggested to 
have functions beyond telomere maintenance (99), we examined mTR-deficient 
mice (lacking only the telomerase RNA template) to avoid any such non-
telomeric effects and instead focus on the consequences of telomere 
dysfunction.   
METHODS 
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Microarray target preparation, hybridization and analysis 
Microarray experiments were conducted by the University of Pennsylvania 
Molecular Profiling Facility, including quality control tests of the total RNA 
samples by Agilent Bioanalyzer and Nanodrop spectrophotometry.  Crypt and 
stromal RNA was obtained, respectively, from three or two wild type and three or 
four G4 mTR-/- mice, with samples from each mouse analyzed on an individual 
array.  All protocols were conducted as described in the Ambion WT Expression 
Manual and the Affymetrix GeneChip Expression Analysis Technical Manual, 
using 250 ng of total RNA for first-strand cDNA synthesis. cDNA yields ranged 
from 9.4-10.7 µg, and 5.5 µg of labeled cDNA was hybridized to Mouse Gene 
1.0ST GeneChips, stained with streptavidin-phycoerythrin, and visualized with a 
GeneChip 3000 7G scanner.  Affymetrix probe intensity (.cel) files were imported 
into Partek Genomics Suite (v6.6, Partek Inc., St. Louis, MO) where RMA 
normalization was applied. The resulting log2-transformed intensities were 
filtered to exclude the IDs corresponding to technical controls, and analyzed for 
differential expression using SAM (Significance Analysis of Microarrays, samr 
v2.0, Stanford University (251)), generating q-values (False Discovery Rate) and 
fold change for each Transcript ID. 
Heat map and gene set enrichment analysis (GSEA): 
Heat maps were generated with Multiple Experiment Viewer (MeV) (252) v4.8.1 
from the Dana-Farber Cancer Institute. GSEA (253) v2.0.13 from the Broad 
Institute was used to identify significant enrichments in the microarray data. The 
C2 collection containing 4850 curated gene sets from the Molecular Signature 
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Database (MSigDB) v3.1 was used to identify enriched pathways in WT vs. G4 
mTR-/- crypts. Chip2Chip was used to translate gene identifiers from the C2 
collection to the Affymetrix Mouse Gene 1.0ST probeset IDs. GSEA was 
performed as follows: log2-transformed RMA values from each individual sample 
were used for the expression dataset. Parameter details are as follows: 
Permutations: 1000, ‘Collapse dataset’ = FALSE, Permutation type = gene_set, 
Max size = 5000, Min size = 1. GSEA was also performed using user-defined 
gene sets from the transcriptomic profile of ISCs or downregulated genes in 
Lgr4/5 KO crypts, described as follows. 361 genes out of 379 genes defined as 
the transcriptomic profile of Lgr5+ ISCs on the Affymetrix platform (249) matched 
the Affymetrix Mouse Gene 1.0ST platform that was used for measurements, and 
these were used to generate the heat map and GSEA enrichment plot. We also 
used the 125 genes out of 135 genes defined as the ISC transcriptome (237) that 
matched our microarray platform. For the gene set describing downregulated 
genes in Lgr4/5 KO crypts (167), 259 of 306 genes from the array platforms 
matched the Affymetrix platform and were used in GSEA. GSEA was performed 
for proliferating (PD32) and replicatively senescent (PD88) IMR90 cells using 
publicly available Gene Expression Omnibus (GEO) dataset GSE36640 (83). 
Chip2Chip was used to translate gene identifiers from the C2 collection to the 
Affymetrix Human Genome U133 Plus 2.0 Array. GSEA was performed as 
follows: raw dataset values from each individual sample were used for the 
expression dataset. Parameter details are as follows: Permutations: 1000, 
‘Collapse dataset’ = FALSE, Permutation type = gene_set, Max size = 10000, 
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Min size = 5, and 4721 out of 4722 C2 collection of gene sets from MsigDB v4.0 
passed the criteria for analysis. 
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RESULTS 
ISC abnormalities in mice with dysfunctional telomeres are specific to Wnt-
responsive stem cell markers 
Crypt epithelium and underlying stroma were each isolated from wild type (WT) 
and G4 mTR-/- mice and used for mRNA expression profiling.  Gene set 
enrichment analysis (GSEA) (253) allowed us to take an unbiased approach to 
determine which gene sets amongst the 4000+ curated gene sets in the 
Molecular Signature Database are significantly down or upregulated in our G4 
mTR-/- crypts. One of the sets most significantly downregulated in the mutant 
crypts is that with genes similarly downregulated in crypts upon deletion of β-
catenin, the key mediator of Wnt signaling between the cytoplasm and nucleus 
(NES -2.27, FDR <0.0001; Table 3.1 and Figure 3.1). Also significantly 
downregulated were gene sets involved in stem cell maintenance (TLX-
dependent) and cell cycle progression (E2F3-dependent), consistent with stem 
cell defects.   
Table 3.1. Gene set enrichment analysis (GSEA) of G4 mTerc-/- versus WT 
intestinal crypts. Top 5 gene sets downregulated in G4 mTerc-/- crypts compared to WT 
crypts as determined by GSEA, using the C2 (curated) database of gene sets published 
in the Molecular Signature Database version 3.1.  
Gene set name 
in MSigDB 
Enrichment 
Score 
Normalized 
ES 
FDR Gene set description 
ZHANG_TLX_TA
RGETS_UP -0.75 -2.41 0.000 
Genes upregulated in neural stem 
cells after cre-lox TLX knockout 
FEVR_CTNNB1_
TARGETS_DN -0.58 -2.27 0.000 
Genes downregulated in 
intestinal crypt cells upon β-
catenin deletion 
PUJANA_XPRES
S_INT_NETWOR
K -0.65 -2.36 0.000 
Intersection of genes correlating 
with BRCA1, BRCA2, ATM, and 
CHEK2 in normal tissues 
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REN_BOUND_BY
_E2F -0.69 -2.32 0.000 
Genes whose promoters were 
bound by E2F1 and E2F4 by ChIP 
in WI-38 fibroblasts 
PUJANA_BRCA_
CENTERED_NET
WORK -0.66 -2.31 0.000 
Genes constituting the BRCA-
centered network (genes 
potentially associated with higher 
breast cancer risk) 
 
Figure 3.1. Gene set enrichment analysis plots of G4 mTR-/- versus WT 
intestinal crypts. GSEA plot comparing genes with altered expression in the 
intestinal crypts of G4 mTR-/- mice vs those downregulated in b-catenin knockout 
mice (FEVR_CTNNB1_TARGETS_DN) 
Examination of Wnt-dependent ISC gene expression, including in situ 
hybridization for Ascl2 mRNA (CBC-specific) and immunofluorescent staining for 
Sox9 protein (expressed in CBCs and transit amplifying (TA) cells) revealed 
dramatically decreased expression in late generation (G4) mTR-/- mice (Figure 
3.2).  There was no difference in the expression of Msi1 protein, an ISC marker 
that is expressed in a Wnt-independent fashion in +4 LRCs and that persists into 
CBCs (254, 255) (Figure 3.2). The minimal changes in Ascl2 and Sox9 
expression in G2 mice indicates the defective expression is caused by 
dysfunctional telomeres rather than telomerase deficiency per se.  
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53	  
 
Figure 3.2. Defects in small intestinal Wnt-dependent stem cell markers in 
late-generation mTR-/- mice. In situ hybridization for Ascl2 transcripts (top 
panel) and immunostaining for Sox9 (middle panel) and Msi1 (bottom panel) in 
ileum from wild-type and G2 and G4 mTR-/-mice. N = 3 mice of each genotype for 
Ascl2 and Msi1 staining; N = 5 WT mice, 2 G2 mice, and 4 G4 mice for Sox9 
staining, * p<0.05. Scale bars: 100µm (top) and 50µm (middle and bottom). 
Since multiple cell types (Paneth cells, +4LRCs, CBCs, TA cells) reside in 
crypts, changes in expression profiling could reflect gene expression changes in 
several cell populations or in a single cell type, or it could reflect a change in the 
composition of cells that make up the crypt. We wanted to determine whether the 
alteration in expression profiling reflects a change in a specific pathway (i.e. beta-
catenin) or a change in the cellular makeup of the crypt. Staining for lysozyme-
positive granules characteristic of Paneth cells revealed neither loss of these 
cells nor of interposed cells (Figure 3.3), which is where CBCs reside in normal 
mice. Thus, the diminished expression of CBC marker genes apparently reflects 
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changes in the state, rather than the presence, of CBCs. This conclusion was 
also supported by several additional findings, as described below.  There were 
also no significant changes in genes expressed in +4LRCs including Bmi1, 
mTert, Hopx, and Lrig1 (Figure 3.4). Because +4LRCs are independent of Wnt, 
this suggests maintenance of some or all Wnt-independent pathways in the 
mutants.  We conclude that expression of at least some CBC-specific genes 
targeted by the canonical Wnt pathway is compromised in mice with 
dysfunctional telomeres caused by generations of telomerase deficiency. 
 
Figure 3.3. CBCs numbers are unchanged in wild-type and G4 mTR-/- ileum. 
Immunostaining for Paneth cell lysozyme in wild-type and G4 mTerc-/- ileum and 
β-catenin staining marks cell peripheries (top panel). (Middle panel) The enlarged 
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insets show examples of cells at the normal CBC location between lysozyme-
positive Paneth cells. Quantitation of Paneth cell counts (top right panel) and 
intercalated cells (bottom panel) from wild-type and G4 mTR-/- crypts. N = 6 of 
each genotype for lysozyme staining, * p<0.05. Scale bars: 50µm. 
 
 
Figure 3.4. Wnt-independent ISC marker gene transcript levels are 
unchanged in intestinal crypts of mTR-/- mice. Microarray signals of Wnt-
independent ISC marker genes in WT and G4 mTR-/- crypts. 
Broadly abnormal expression of Wnt pathway genes in G4 mTR-/- crypt 
epithelium and underlying stroma. 
Wnt ligands produced by stromal and Paneth cells provide support 
essential to CBC function (177).  Because Ascl2 and Sox9 are direct targets of 
the Wnt signaling pathway, we hypothesized that their diminished expression in 
G4 mTR-/- crypts reflects a defect in the Wnt pathway caused by telomere 
dysfunction. qRT-PCR was used to verify the altered expression of a number of 
the Wnt pathway and target genes, including Wnt3, Lrp6, and Lgr5 (Figure 3.5).  
The decline in Wnt3 transcripts is particularly revealing, because it occurred even 
though 1) Paneth cells are the only apparent intestinal source of Wnt3 (177), and 
2) there is no loss of Paneth cells in G4 mTR-/- crypts (Figure 3.3), thus 
confirming downregulation of Wnt pathway genes independent of cell losses. 
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Figure 3.5. G4 mTR-/- mice have reduced expression of pro-Wnt pathway 
genes in ileal crypts and stroma. qRT-PCR analyses of gene expression for 
the Wnt ligand (Wnt3), Wnt co-receptor (Lrp6), and Wnt target gene (Lgr5) in WT 
and G4 mTR-/-  crypts (left). qRT-PCR analyses of gene expression for the Wnt 
ligand (Wnt4) and Wnt receptor inhibitor (Sfrp3) in WT and G4 mTR-/- stroma 
(right). N = 4 mice per genotype, * p<0.05, *** p<0.005. 
 
In the stroma, expression changes were also consistent with decreased 
Wnt pathway activity, including upregulation of several of the SFRP Wnt 
antagonists (Figure 3.5 and 3.6). Several Wnts and cell surface receptors (Fzds) 
were also downregulated in G4 mTR-/- crypts (Figure 3.6).  qRT-PCR confirmed 
the altered expression of Sfrp3 and Wnt4 (Figure 3.5).  Collectively, the data from 
epithelium and stroma indicate broad suppression of Wnt pathway components 
in G4 mTR-/- intestinal tissues.  
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Figure 3.6. Microarray 
gene profiling of the 
small intestinal stroma 
and epithelium of WT 
and G4 mTR-/- crypts.  
Affymetrix Mouse Gene 
1.0ST microarray 
analyses of mRNA levels 
were performed on crypts 
or stroma each isolated 
from wild-type and G4 
mTR-/- mice.  Examples 
indicating downregulation 
of multiple Wnt pathway 
genes (i.e. Wnt ligands 
and receptors) and 
upregulation of Wnt 
ligand inhibitors (i.e. 
stromal SFRPs) in G4 
mTR-/- intestine, which 
support the GSEA 
analyses (see Figure 
S3).  (A) Fold changes of 
SFRPs (Wnt ligand 
inhibitors) in G4 mTR-/- 
intestinal stroma. (B) 
Fold changes of Wnt 
ligands in G4 mTR-/- 
intestinal crypts and (C) 
stroma; Wnt ligands 
known to be expressed in 
robust amounts in each 
compartment are 
highlighted in purple. (D) 
Fold changes of Fzd 
genes (Wnt ligand 
receptors) in G4 mTR-/- 
intestinal crypts. * p<0.05 
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Based on defects in G1 mTert-/- but not G1 mTR-/- mice, Park et al. (99) 
have suggested that Tert but not TR regulates Wnt signaling, and does so 
independent of its telomere-lengthening function. As discussed in the introduction, 
this idea has been questioned, and moreover is a story that is quite separate 
from ours.  First, our mice are genetically deficient for mTR and not mTert, and 
indeed levels of mTert transcripts were not decreased in late-generation mTR-/- 
crypts (Figure 3.4), consistent with published findings (256). Second, the 
suppression of Wnt pathway gene expression progressed with successive 
generations of telomerase deficiency (Figure 3.2), confirming that telomere 
dysfunction, rather than telomerase deficiency per se causes the suppression.  
We wanted to see if telomere dysfunction induces Wnt signaling 
suppression in other cell types as well, and we mined the GEO database for 
expression profiles of cells with telomere dysfunction, and we focused on a 
dataset that compared early-passage proliferating to replicatively senescent 
IMR90 fibroblasts (83). GSEA reveals that Wnt pathway gene sets are 
significantly downregulated within cells that have senesced due to telomere 
shortening (Table 3.2). Similarly, the expression of Axin2 (the ubiquitous and 
canonical Wnt target gene in all cells) was significantly decreased in primary 
human fibroblasts from patients with telomere dysfunction, namely dyskeratosis 
congenita (Figure 3.7). Furthermore, in primary human fibroblasts with Wrn 
mutations (which causes telomere dysfunction), Axin2 expression is rescued 
once telomere capping is restored (with hTERT overexpression) (Figure 3.7). 
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These data strongly support that telomere dysfunction result in a suppression of 
Wnt signaling.  
 
Table 3.2. Gene set enrichment analysis (GSEA) of Wnt pathway related 
gene sets significantly enriched in proliferating versus replicatively 
senescent IMR90 cells. Wnt pathway related gene sets enriched in proliferating 
(PD32) as compared to senescent (PD88) IMR90 cells (from GSE36640 dataset 
of GEO), as determined by GSEA using the C2 (curated) database of 4722 gene 
sets as published in the Molecular Signature Database version 4.0.   
Gene set name in 
MSigDB 
Enrichment 
Score 
Normalized 
ES 
FDR Gene set description 
FEVR_CTNNB1_TA
RGETS_DN 0.64 2.16 0.000 
Genes downregulated in 
intestinal crypt cells upon β-
catenin deletion 
LABBE_WNT3A_TA
RGETS_UP 0.55 1.69 0.005 
Genes upregulated in NMuMG 
cells after Wnt3a stimulation 
FIRESTEIN_CTNNB
1_PATHWAY 0.65 1.67 0.006 
Genes required for and β-
catenin activation in APC colon 
cancer cells 
FIRESTEIN_CTNNB
1_PATHWAY_AND_ 
PROLIFERATION 0.75 1.67 0.006 
Genes required for proliferation 
and β-catenin activation in APC 
colon cancer cells 
 
 
Figure 3.7. qRT-PCR analysis of Axin2 expression in primary human 
fibroblasts with telomere dysfunction. Expression of AXIN2 mRNA levels in 
primary human fibroblasts from (left panel) three healthy people (WT) and two 
people with dyskeratosis congenita (DC), and (right panel) a person with Werner 
syndrome (WS) infected with retrovirus expressing hTERT or a vector control. * 
p<0.05 
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DISCUSSION 
Our study reveals that loss of telomere capping can lead to broad suppression of 
Wnt pathway components and activities in the mouse intestine.  Expression of 
multiple Wnt pathway genes, from those encoding Wnt ligands and receptors, to 
those that are targets of Wnt-dependent transcription factors, is reduced in the 
intestinal crypts of late generation mTR-/- mice.  The changes are most 
pronounced in crypt epithelium, but also occur in the underlying stroma, including 
enhanced expression of Wnt pathway inhibitors, which may contribute to 
inhibition of signaling.  The progressive nature of these changes with increasing 
generation of mTR-/- mice, indicates that uncapped telomeres are the basis for 
Wnt suppression, rather than telomerase deficiency per se. 
 We considered the possibility that the Wnt pathway suppression might be 
secondary to losses in cells expressing these genes, rather than downregulation 
in extant cells.   Our observations argue against this.  First, Wnt3 transcript levels 
decline in the intestinal epithelium of G4 mTR-/- mice, even though Paneth cells, 
which are the sole expressors of Wnt3 in this tissue, are not lost.  Second, even 
though the expression of CBC marker genes (e.g. Lgr5, Ascl2, Sox9, all of which 
are Wnt-dependent) declined, there were no losses of cells intercalated between 
Paneth cells, which is where CBCs reside, indicating a change in CBC state 
rather than survival.  We emphasize that because the defining gene expression 
signature of CBCs depends entirely on Wnt pathway genes, it is not possible to 
use such expression to enumerate CBCs in the G4 mice.  Third, we observed a 
gradual loss in Ascl2 and Sox9 levels in earlier generations of mTR-/- mice (e.g. 
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intermediate losses in G2 mice; Figure 3.2), indicating declines in expression 
precede frank losses.  Fourth, examination of microarray expression data from 
proliferative and replicatively senescent IMR90 fibroblasts (83) reveals that Wnt 
pathway gene sets are significantly downregulated within cells that have 
senesced due to telomere shortening (Table 3.2), and such downregulation 
occurs in a setting where changes in gene expression cannot be explained by 
cell losses. 
It would be ideal to explore changes in gene expression specific to a 
single cell type (i.e. CBCs) with telomere dysfunction, since the crypt contains 
many populations of cells and the changes we detect may reflect changes in 
more than one cell type. We considered crossing mice with reporters for ISC-
markers (e.g. Lgr5-EGFP or Axin2-TdTomato mice) onto our mTR-/- mice to sort 
out CBCs and perform expression profiling on an enriched population of CBCs. 
However, since there are no known Wnt-independent markers specific to CBCs 
(241), and the phenotype we observe is a suppression in Wnt signaling, we 
would be sorting and selecting for a population of CBCs that have strong Wnt 
signaling and not as severe a phenotype as we would otherwise see.  
Given these constraints, we have proposed future experiments that may 
address some of the pitfalls in the design of our original experiments. To address 
whether acute telomere uncapping results in Wnt pathway suppression, we have 
recently developed a system of where we can acutely induce telomere 
dysfunction in organoid cultures established from the Axin2-TdTomato reporter 
mouse. We have cloned and infected a Tet-On lentiviral system to express a 
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dominant negative form of Trf2, which rapidly uncaps telomeres, in Axin2-
TdTomato organoids. Axin2 is expressed predominantly in the CBCs (Figure 
3.8). If our hypothesis is correct, we expect to see decreased TdTomato intensity 
(i.e. decreased Wnt target gene expression) upon acute telomere uncapping. We 
hope to track Axin2-TdTomato intensity before cells die from critical telomere 
shortening but after telomeres are uncapped, to ensure that any loss of signal 
intensity is not due from dying cells. We plan to use real-live imaging and flow 
cytometry to track and measure Axin2-TdTomato intensity upon induced 
telomere uncapping over time, which will inform us of the Wnt signaling status.  
 
Figure 3.8. Wnt reporter Axin2-TdTomato organoid vs WT organoid in 
culture. (Left panel) Axin2-TdTomato organoids grown in culture and (right 
panel) wild-type organoid grown under the same conditions. Brightfield image 
superimposed on fluorescent image taken with a Cy3 filter. Autofluorescence in 
central lumen of organoid (dashed line). 
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CHAPTER 4: P53 AND MIR-34A IN WNT SUPPRESSION  
INTRODUCTION 
When expression of many components of the Wnt pathway are 
downregulated (and not just the targets of Wnt signaling, but components at 
multiple steps of the pathway), one wonders whether there is a master conductor 
or several different regulators that can specifically target the pathway. There are 
a few hypotheses that we generated for the mechanism of Wnt pathway 
suppression, which we outline below.  
Wnt pathway suppression has been attributed to p53 activation, 
specifically through downstream targets of p53, SIAH1 and miR-34a (223, 226). 
SIAH1 is an E3 ubiquitin ligase transcriptionally activated by p53, and it targets 
beta-catenin protein for degradation, and simultaneously targets TRF2 protein for 
degradation during p53-activated replicative senescence of human cultured cells 
(151, 257). In our experiments, RNA levels of beta-catenin are unchanged in G4 
crypts compared to WT crypts on microarray, and Trf2 RNA levels are decreased 
(on microarray and confirmed by qRT-PCR). Siah1 is not expected to change 
RNA levels of beta-catenin or Trf2, and therefore the decreased Trf2 levels that 
we observe in G4 crypts are presumably due to other factors. Although we have 
not confirmed Siah1a or Siah1b upregulation in G4 crypts by qRT-PCR or WB, 
our microarray results suggest that altered Siah1 expression does not explain 
Wnt pathway downregulation in the intestinal crypt epithelium of mice with 
uncapped telomeres. 
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p53 has been conditionally knocked out in the intestine of mTR-/- mice 
(156), and downstream components of p53, p21 and PUMA, have also been 
knocked out in mTR-/- mice (161, 162). G4 mTR-/- mice lacking intestinal p53 had 
rescue in the expression of the CBC marker, Olfm4, which is a target of Ascl2, 
itself a Wnt target gene. These mice had increased crypt proliferation but also 
increased crypt genomic instability (characterized by increased telomere 
dysfunction and DNA damage responses) and apoptosis (156). Overall, this 
strongly suggests that p53 activation mediates the suppression of CBC marker 
expression in late generation mTR-/- crypts. Given that miR-34a is direct 
transcriptional target of p53 that has been found to suppress expression of 
multiple genes of the Wnt pathway (258, 259), it is plausible to hypothesize that 
miR-34a mediates the suppression of Wnt pathway components that we observe.  
Several miRNAs have been described to be upregulated in aged tissues 
and associate with senescence pathways. miRNAs can downregulate a whole 
class of genes, and miRNAs (specifically miR-34a) are good candidates for the 
mechanism of suppressed expression of multiple Wnt pathway genes upon 
telomere uncapping and p53-activation (260, 261). miR-34a is of particular 
interest, as it is implicated in the DNA damage response pathway and aging, 
including cardiac aging and aging skeletal muscles (262). miR-34a belongs to a 
family of miRNAs that include miR34b and miR34c. miR-34a is encoded on 
chromosome 4 of mice and chromosome 1 of humans, while miR34b and 
miR34c are both 500bp within each other on the same chromosome 9 in mice 
and 11 in humans. miR-34a has tumor suppressor activities and is activated by 
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p53, which is activated upon DNA damage including telomere dysfunction. There 
are also other important miRNAs that may be important in gene regulation in the 
G4 crypts.  
Deletion of chromosomal region 1p36, where miR-34a is located but no 
other tumor suppressor genes are, has been described in various cancers, 
including colon cancer (263, 264). miR-34a-knockout mice on a normal C57BL/6 
background, however, have no obvious developmental or pathological 
abnormalities up to 12 months (265). Apparent phenotypes include increased 
somatic reprogramming efficiency of miR-34a-/- MEFs and increased bone 
resorption and reduced bone mass (266). However, in aged mice, miR-34a 
contributes to cardiac aging in mice in part due to its inhibition of PNUTS, which 
binds to TRF2 to prevent telomere shortening (262). miR-34a is directly 
downstream of the p53-activation pathway and has also been shown to have a 
feed-forward effect on p53 activation through inhibition of Mdm4, an inhibitor of 
p53 (267). Other important targets of miR-34a include SIRT1 (268), and 
interestingly, multiple genes of the Wnt pathway, namely Wnt1, Wnt3, Lrp6, beta-
catenin, and Lef1. We hypothesize that miR-34a mediates part of the pathology 
we observe in G4 crypts, specifically, the decreased expression of Wnt pathway 
genes that we have observed.  
METHODS 
MicroRNA microarray 
Microarray experiments were conducted by the University of Pennsylvania 
Molecular Profiling Facility, including quality control tests of the total RNA 
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samples by Agilent Bioanalyzer and Nanodrop spectrophotometry.  Crypt RNA 
was obtained from three G4 mTR-/- mice, with samples from each mouse 
analyzed on an individual array.  Amplification steps were performed with the 
Genisphere FlashTag (miRNA) kit and the Affymetrix GeneChip miRNA 3.0 Array 
chips were used. Affymetrix probe intensity (.cel) files were imported into Partek 
Genomics Suite (v6.6, Partek Inc., St. Louis, MO) where RMA normalization was 
applied. The resulting log2-transformed intensities were filtered to exclude the 
IDs corresponding to technical controls, and analyzed for differential expression 
using SAM (Significance Analysis of Microarrays, samr v2.0, Stanford University 
(251)), generating q-values (False Discovery Rate) and fold change for each 
Transcript ID. 
Mice 
The breeding scheme for generating miR-34a-/- onto the different generations of 
mTR-/- mice is outlined in the following diagram. For simplicity, we will refer to the 
genotype of mTR-/- by generation (e.g. G1 for first generation mTR-/- mice) and 
we will refer to the genotype of miR-34a by allele status (e.g. WT for miR-34a+/+, 
HET for miR-34a+/-, and KO for miR-34a-/-). For example, a third-generation mTR-
/- mouse heterozygous for miR-34a is referred to G3-het. 
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Lentiviral infection of crypt organoid cultures 
Lentiviruses were made at the Wistar Vector Core from System Biosciences 
MirZip vectors coding for with anti-microRNAs: MirZip scramble control vector 
and MirZip vector targeting miR-34a. Organoids were cultured and established in 
5 µM CHIR conditions for several passages before infection. Organoids 
embedded in Matrigel were counted and washed once with cold PBS, and the 
organoids and Matrigel were broken up by pipetting. Organoids were spun down 
at 300g in a cold centrifuge and resuspended in culture media containing 5 µM 
CHIR. Lentiviruses were added to the organoid suspension at different 
multiplicities of infection (MOI of 25 or 50) for 4-6 hours in a 37°C incubator. After 
incubation, organoids were collected and spun down at 300g, resuspended in 
Matrigel, plated, and grown at 5 µM CHIR for 2-3 days before 2 µg/mL puromycin 
selection.  
	    
mTR+/- x miR-34a-/- 
ê 
G1mTR-/- miR-34a+-/
 
x G1mTR-/-
 
miR-34a+/- (G1-het x G1-het) 
ê 
G2-het x G2-het 
ê 
G3-het x G3-het 
ê 
G4-WT; G4-het; G4-KO 
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RESULTS 
We performed a microRNA microarray on WT and G4 crypts (n=3 each) 
using service from the UPenn Pathology Core (using standard core suggested 
preparation methods for the Affymetrix GeneChip miRNA 3.0 Array) (data tables 
in Appendix). Since the chip contains many probes for miRNAs and pre-miRNAs 
that are not yet experimentally determined and are based on unvalidated in silico 
data (from miRBase version 17), we can rely on the newer version of the online 
miRBase database (currently at version 21) to investigate individual miRNA hits. 
miRBase contains information about read counts from available deep sequencing 
experiments, predicted mRNA targets, experimentally-validated mRNA targets, 
etc. Out of the top 10 upregulated miRNA in G4 crypts, 8 miRNAs do not have 
validated mRNA targets or are misannotated. For example, the second most 
increased miRNA hit, miR-5097, is noted to be a misannotation on miRBase and 
is actually derived from a fragment of tRNA and it is not processed by Dicer or 
loaded into RISC. A large proportion of the top 100 upregulated miRNAs belong 
to the misannotated class or have yet to be experimentally identified. miR-34a is 
the most upregulated (validated) miRNA in G4 crypts.  
There are several other interesting validated miRNAs that have 
significantly upregulated expression in G4 crypts, including the miR-23a~27a~24-
2 cluster . The miR-23a~27a~24-2 cluster is encoded by a single pri-miRNA that 
generates 3 different mature miRNAs: 23a, 27a, and 24-2. In many pathological 
conditions the cluster is overexpressed, such as in cancer. In silico analysis has 
shown the cluster to regulate many genes of the Wnt pathway: Wnt3a, Wnt4 are 
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targeted by miR-27a and -24a, respectively; Lrp5 and Lrp6 by miR-23a and -27a 
respectively; Fzd4 and Fzd7 by both miR-23a and -27a; Dvl1 by miR-27a; Tcf7 
by miR-24. The Wnt target gene Cyclin D is also targeted by miR-23a. 
Conversely, inhibitors of the Wnt pathway are also targeted – APC by miR-23a 
and PP2A by miR27a. However, these Wnt pathway gene targets of the miR-
23a~27a~24-2 cluster have not been experimentally validated (269). We focus 
on miR-34a because it has been consistently described and validated to be 
overexpressed in multiple different tissues across species with aging and DNA 
damage responses. 
How expression of Wnt pathway components is broadly downregulated in 
the intestines of late-generation mTR-/- mice is not yet clear.  However, it is well 
established that dysfunctional telomeres elicit a p53-dependent DNA damage 
response, and p53-activated upregulation of miR-34a has been implicated 
recently in the suppression of multiple Wnt pathway genes (258).  Indeed, we 
detected increasing levels of p53 activation (as measured by p21 expression, 
Figure 4.1) with successive generations of mTR-/- crypts along with a 
corresponding decrease in Wnt target genes, Lgr5 and Trf2 (Figure 4.1), and the 
suppression in Wnt signaling corresponds to levels of p53 activation. We have 
validated the increased expression of miR-34a by qRT-PCR in G4 crypts 
compared to WT. Indeed, there is an incremental increase in miR-34a expression 
with increasing generations of mTR-/- mice (Figure 4.1). The incremental increase 
in miR-34a also corresponds to the incremental decrease in Wnt target genes, 
consistent with others’ observation of miR-34a activation by p53 to suppress 
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expression of Wnt pathway genes. One of the targets of miR-34a is PNUTS, 
which has been described to maintain telomere length through its interaction with 
TRF2. As expected, PNUTS is downregulated in G4 crypts (Figure 4.2), which 
may contribute to the further uncapping of telomeres.  
 
Figure 4.1. Expression of p53-activated genes, Wnt target genes in WT and 
mTR-/- crypts. qRT-PCR of p21, mir-34a, Lgr5, and Trf2 in WT, G2, G3, and G4 
mTR-/- crypts. 
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Figure 4.2. Expression of miR-34a target gene PNUTS in WT and G4 mTR-/- 
crypts. qRT-PCR of PNUTS in WT and G4 mTR-/- crypts. 
Given the considerations described above, it is plausible that miR-34a 
contributes to the suppression of the Wnt pathway in intestinal crypts of late-
generation mTR-/- mice. To test this hypothesis, we crossed the miR-34a-/- mouse 
onto the mTR-/- background. The breeding scheme (described in the Methods 
section) allows us to obtain mTR-/- mice at each generation with the proper 
littermate controls: miR-34a+/+, miR-34a+/-, and miR-34a-/-. In early generations 
(G1-3) of mTR-/-, mice were born with the expected miR-34a+/+, miR-34a+/-, and 
miR-34a-/- Mendelian frequencies (Table 4.1). In the 4th generation, the birth 
frequency is skewed towards more mTR-/- mice being born with miR-34a-/- (Chi-
squared p-value of 0.1170), which suggests that there is an embryonic/neonatal 
survival advantage of miR-34a-/- at later generations of mTR-/-, when telomeres 
become critically short and when p53 and miR-34a activation would occur.  
Since miR-34a activation occurs after telomeres become dysfunction, we 
do not see any survival advantage of miR-34a deletion until later generations. 
And since there is a large variation in telomere lengths and consequently varying 
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degrees of telomere dysfunction within the same generation, and even amongst 
littermates (270), larger sample sizes are necessary to provide us with more 
substantial and significant evidence of any survival advantages of miR-34a 
deletion. Indeed, the telomere length variation that exists amongst mice of the 
same generation might also explain why there seem to be certain G3 breeding 
pairs that produce G4 pups at the expected miR-34a Mendelian frequency and 
other breeding pairs that only produce G4 pups with miR-34a-/- or miR-34a+/- but 
no miR-34a+/+ (not shown). We have not yet measured telomere lengths in the 
different breeding pairs, but we hypothesize that the former pairs would have 
longer telomeres than the latter pairs. 
Table 4.1. Actual vs. expected Mendelian frequencies of miR-34a+/+, miR-
34a+/-, and miR-34a-/- in G2, G3, and G4 mTR-/- mice. Chi-squared test two-
tailed p-values are 0.3198, 0.9350, and 0.1170, for G2, G3, and G4 mTR-/- mice, 
respectively. 
G2 mTR-/- Actual genotype Expected genotype Total pups 
+/+ 8 12.5 50 
+/- 29 25  
-/- 13 12.5 
 
 
G3 mTR-/- Actual genotype Expected genotype Total pups 
+/+ 16 16.75 67 
+/- 33 33.5  
-/- 18 16.75  
 
G4 mTR-/- Actual genotype Expected genotype Total pups 
+/+ 13 19.75 79 
+/- 40 39.5  
-/- 26 19.75  
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We have isolated crypts for organoid culturing from two pairs of G4 
littermates with miR-34a+/+ and miR-34a-/- statuses. We also obtained crypts from 
a G4 miR-34a+/- littermate for one experiment, from which we also cultured 
fibroblasts from ears. In addition, we are currently performing miR-34a 
knockdown experiments with lentiviral vectors expressing anti-miR-34a shRNAs 
in G4 miR-34a+/+ organoids and ear fibroblasts. Ear fibroblast and anti-miR-34a 
shRNA experiments are ongoing, and we will not present those results here. Our 
preliminary data indicate a survival advantage in G4 organoids lacking miR-34a 
over those with intact miR-34a (Figure 4.3 and 4.4), with increased expression of 
the Wnt target gene, Lgr5 (Figure 4.5). It would be necessary to do parallel 
control experiments comparing WT vs miR-34a-/- mice or early generation G1 
miR-34a+/+ vs G1 miR-34a-/- mice, where we would not expect a survival 
advantage in organoids lacking miR-34a.  
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Figure 4.3. G4miR-34a+/+ and G4miR-34a-/- organoid survival 8 days after 
harvest (left panel) or loss from 4 to 8 days after ex vivo harvest (right 
panel). Intestinal organoids were harvested from one pair of G4miR-34a+/+ and 
G4miR-34a-/- littermates and cultured under standard conditions (1 µg/ml Rspo1) 
or augmented with the GSK-3 inhibitor CHIR99021. N=20 wells at 0µM, 8 wells 
at 1µM, and 5 wells at 2µM and 5µM CHIR; *p<0.0005 
 
 
Figure 4.4. G4miR-34a+/+ and G4miR-34a-/- organoids in culture with 
CHIR99021. Representative brightfield images of intestinal organoids harvested 
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from one pair of G4miR-34a+/+ and G4miR-34a-/- littermates and cultured under 
standard conditions (1 µg/ml Rspo1) or augmented with the GSK-3 inhibitor 
CHIR99021. 
 
 
Figure 4.5. qRT-PCR analysis of Lgr5 expression in G4miR-34a+/+ and 
G4miR-34a-/- organoids 8 days after ex vivo harvest. qRT-PCR measurement 
of Lgr5 transcripts in G4miR-34a+/+ and G4miR-34a-/- littermate organoids 8 days 
after crypt harvest, and treated with 5µM CHIR99021. N=1 for G4miR-34a+/+ and 
N=2 for G4miR-34a-/- organoids. 
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DISCUSSION 
How uncapped telomeres lead to repressed expression of Wnt pathway 
factors in the intestine of late generation mTR-deficient mice is not yet clear.  
However, it is well established that uncapped telomeres activate p53-dependent 
responses, and recently the p53-activated miRNA-34a was found to inhibit 
expression of Wnt pathway genes (258, 260), including many of those we find 
downregulated in G4 mTR-/- crypts.  We observe increased expression of miR-
34a in late generation mutant crypts, where it could contribute to such inhibition. 
Consistent with this idea, Wnt pathway gene suppression caused by uncapped 
telomeres likely depends on p53, as deletion of p53 in late-generation mTR-/-
 mice rescues expression within intestinal CBCs of Olfm4 (156), which is a target 
of the Wnt-activated transcription factor Ascl2 (237).  
The experiments that we have designed and presented above have begun 
to address the hypothesis that miR-34a contributes to the suppression of Wnt 
pathway genes we observe in G4 crypts. The fact that we see a trend toward a 
perinatal survival advantage from miR-34a deletion only in later generations of 
mTR-/- mice, informs us that miR-34a may have effects beyond the regulation of 
Wnt suppression in the intestinal crypt. Currently, all of the mice we have not 
sacrificed for experiments are still alive and since most of these mice are still 
relatively young, we have not yet had the opportunity to perform a survival curve. 
We are currently starting to characterize these mice and to perform functional 
experiments. We would like to assess for telomere capping status through 
metaphase-TIFs in G4 ear fibroblasts and organoids lacking miR-34a. 
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We have only concentrated our efforts thus far on miR-34a, which is 
upregulated in G4 crypts, but of equal interest are miRNAs that are significantly 
downregulated in G4 crypts. One of the top most downregulated miRNAs belong 
to that of the miR-181, miR-30, and miR-200 families, and each family play 
important roles in cancer, inflammation, and development. As mentioned in the 
introduction, the miR-17-92 family cluster that is consistently downregulated in 
aging, is also significantly downregulated in G4 crypts. Any of these and other 
miRNAs that are significantly changed in G4 crypts may play important functional 
roles in the pathophysiology or downstream effects of telomere dysfunction. A 
high-throughput approach to assess the functional role of specific miRNAs does 
not currently exist, but would greatly advance and accelerate the field of miRNA 
research. 
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CHAPTER 5: RESCUE OF TELOMERE DYSFUNCTION IN INTESTINAL 
CRYPTS OF LATE-GENERATION TELOMERASE-KNOCKOUT MICE 
INTRODUCTION 
Our results indicate that G4 mTR-/- ISCs experience a niche poor in the Wnt 
pathway activities that normally support CBCs.  Remarkably, Wnt signaling leads 
to upregulation of target genes that encode key components of the Wnt pathway 
itself, e.g. Lgr5.  Thus, downregulation of Wnt pathway activity could lead to 
further downregulation of expression of pathway components via this feedback 
loop.  In addition, Trf2 is a Wnt target gene that encodes a critical telomere 
capping protein, and thus loss of Wnt pathway activity could lead to enhanced 
telomere uncapping, in turn leading to additional downregulation of Wnt pathway 
as described above. We detect incremental decreases in Trf2 expression that 
mirrored the decrease in Axin2 expression from WT to G2 to G4 crypts, and the 
decrease in Trf2 could theoretically exacerbate the state of telomere uncapping 
in G4 crypts. Based on these considerations, it is reasonable to hypothesize that 
supplementation with exogenous Wnt pathway agonists would ameliorate 
pathology by restoring the niche environment, perhaps including restoration of 
Trf2 expression and rescuing telomere dysfunction. 
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METHODS 
TIF and telomere Q-FISH analyses 
Tissue sections were hybridized with a Cy3-labeled PNA telomere repeat probe 
((CCCTAA)3)and anti-53BP1 antibodies (Novus, NB100-304) as described (16). 
Confocal images were obtained with a Nikon Ti-U inverted microscope with CSU-
10 spinning disk confocal head (Spectral Boralis) using a Nikon Plan APO60x/1.4 
lens and Hamamatsu Orca-ER camera. The Cy3 laser was held at a constant 
intensity to capture all images. Images from mice treated with lithium and Rspo1 
were obtained in 16-bit grey scale and 8-bit RGB24 formats, respectively. To 
measure telomere lengths, quantitative image analysis was performed on 
confocal images using Media Cybernetics and ImageProPlus 7.01 software. The 
DAPI images were used to define the nuclear area in which to measure telomere 
intensities. Images were first deconvoluted, and nuclear outlines of interest were 
drawn and applied as a mask onto the Cy3 images. Cy3 images were also 
deconvoluted, and telomere intensities within each nucleus were obtained (for 
16-bit images applied filters were: 1000-65535 pixel intensity threshold and area 
larger than 11.25sq. microns; for 8-bit images applied filters were: 
density/intensity ratio threshold of 0-254). Statistical analyses were performed 
using the Mann-Whitney U-test. 
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RESULTS 
Wnt pathway agonists rescue survival of G4 mTR-/- crypt epithelial cells in 
vivo and in vitro. 
We examined effects of Rspo1 and the selective GSK-3 inhibitor CHIR99021 on 
epithelial organoids cultured in vitro.  This provided a test of Wnt pathway 
agonists under internally controlled conditions (i.e. on tissues from individual 
mice, rather than between mice).  Under standard culture conditions, wild type 
organoids are long-lived and appear as roughly spherical epithelium surrounding 
a central cavity representing the lumen, and have crypts radiating outward from 
their peripheries. G4 mTR-/- organoids were prone to degeneration and had fewer 
crypts, but Rspo1 or CHIR99021 each improved mutant organoid survival and 
morphology in a dose-dependent manner (Figure 5.1).  Although these agents 
also affected WT organoid survival and morphology, they had more pronounced 
effects on mutant organoids. G4 mTR-/- organoids were larger and grew more 
buds (each bud is representative of an individual crypt) with higher doses of 
CHIR99021 (Figure 5.2). At the highest dose (5µM), the organoids lose the 
budding structures and predominantly obtain the morphology of a large spheroid, 
which has been observed in organoids cultured from crypts with high Wnt 
activity. Cultured G4 mTR-/- organoids had reduced levels of Lgr5 transcripts, 
which were partially rescued by CHIR99021 (Figure 5.3).  Furthermore, 
transcripts encoding the pro-apoptotic protein, Noxa, decreased in proportion to 
CHIR99021 dose (Figure 5.3). In sum, these in vitro data establish roles for Wnt 
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pathway agonists in rescuing abnormalities in G4 mTR-/- crypts related to 
morphology, apoptosis and CBC-related gene expression.   
 
	    
Figure 5.1. Wnt pathway agonists rescue survival and morphology of 
cultured G4 mTR-/- intestinal organoids. (Top panel) Intestinal organoids from 
WT and G4 mTR-/- mice were cultured under standard conditions (1 µg/ml Rspo1) 
or augmented with elevated levels of Rspo1 or the GSK-3 inhibitor CHIR99021. 
The survival index is expressed as a percentage of the number of organoids 
divided by the average maximum number of organoids counted in the viewing 
field (4 viewing fields per sample were counted with a 4x objective). N = 3 for 
Rspo1-treated crypts, N = 6 for CHIR-treated crypts. * p<0.05, ** p<0.005, *** 
p<0.0005, **** p<0.0001 
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Figure 5.2. Bud count of per WT or G4 mTR-/- organoids cultured with 
CHIR99021. G4 mTR-/- organoids were cultured in increasing doses of 
CHIR99021 and counted for the number of buds on each organoid.  
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Figure 5.3. qRT-PCR analysis of Lgr5 and Noxa expression in G4 mTR-/- 
crypts cultured with CHIR99021. qRT-PCR measurement of Lgr5 and Noxa 
transcripts in WT and G4 mTR-/- crypts at t=0, and treated with increasing doses 
of CHIR99021 at days 4 or 8. ** p<0.01, **** p<0.0001. 
 
We also see an improvement of G4 mTR-/- crypts with Wnt pathway 
agonists in vivo. Crypt apoptosis was rescued in G4 mTR-/- mice fed with chow 
containing lithium, a GSK-3 inhibitor and thus a Wnt pathway agonist (Figure 
5.4). Since lithium has effects beyond GSK-3 inhibition, we also treated G4 mTR-
/- mice with a specific Wnt/Lgr5 receptor agonist, Rspo1. Daily subcutaneous 
injection for eight days with Rspo1 significantly decreased crypt apoptosis and 
elevated Ascl2 transcript and Sox9 protein levels (Figure 5.5).  We also observed 
an improvement in villus blunting, although we have not quantified these 
changes. For both sets of treatments, comparisons among control and treated 
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mice were made between littermates, to avoid effects from stochastic differences 
in inherited telomere lengths.  Rescue was not associated with improved 
proliferation in the crypt base as measured by Ki-67 (Figure 5.6), nor increased 
numbers of Paneth cells, but was associated with increased proliferation in the 
TA region. Therefore, reduced apoptosis of crypt epithelial cells along with 
increased TA cell proliferation may contribute to the rescue provided by Wnt 
pathway agonists. 
 
Figure 5.4. TUNEL staining of G4 mTR-/- and Li-treated G4 mTR-/- small 
intestinal crypts. (Top panel) G4 mTR-/- mice were treated with the GSK-3 
inhibitor lithium in dietary chow (0.2% for 3 days followed by 0.4% for 7 days). 
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(Bottom panel) TUNEL staining was performed on the ileal crypts, and apoptotic 
bodies per crypt were counted. N = 3 mice per condition, * p<0.05. 
 
 
 
 
Figure 5.5. Enhanced Wnt signaling rescues G4 mTR-/- crypt apoptosis and 
Wnt-responsive ISC markers in vivo. G4 mTR-/- mice treated for eight days 
with subcutaneous injections of R-spondin1 (Rspo1) have reduced small 
intestinal apoptosis as measured by TUNEL (top panel), increased expression of 
Ascl2 transcripts (middle) and Sox9 protein (bottom). N = 5 control G4 mice and 
4 Rspo1-treated G4 mice for TUNEL staining; N = 3 mice per genotype for Ascl2 
staining; N = 4 control G4 mice and 3 Rspo1-treated G4 mice for Sox9 staining, * 
p<0.05. Scale bars: 20µm (top), 100µm (middle and bottom).
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Figure 5.6. Ki67 staining in WT, G4 mTR-/-, and Rspo1-treated G4 mTR-/- 
small intestinal crypts. (Left panel) Ki67 staining was performed on the small 
intestine of WT, G4 mTR-/-, and Rspo1-treated G4 mTR-/- mice. (Right panel) 
Quantification of crypt bases positive for Ki67 staining. N = 4 WT mice, 5 control 
G4 mice and 5 Rspo1-treated G4 mice, *** p<0.0005, **** p<0.0001. 
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Wnt pathway agonists upregulate shelterin components and rescue 
telomere capping.  
We explored the hypothesis that Wnt pathway agnoists can upregulate 
Trf2 expression in the organoid culture system, and indeed, we observed dose-
dependent upregulation of Trf2 transcripts in G4 mTR-/- crypt cultures treated with 
CHIR99021, thus rescuing the reduced levels of Trf2 transcripts in the mutant 
crypts (Figure 5.6). Other shelterin proteins are also important in the 
maintenance of telomere capping, and we analyzed published datasets to test for 
additional evidence that shelterin genes are regulated by Wnt, and found that a) 
Trf2 transcripts are up and down regulated, respectively, in epithelia from APC-
knockout (271) and β-catenin-knockout mice (272), b) the Wnt-responsive 
intestinal epithelial transcription factor TCF4 is bound at high levels within the 
human TRF2, POT1, and TRF1 genes as assessed by ChIP (from the ENCODE 
database (273)), and c) the expression gradient of these genes within murine 
crypts corresponds to that of the Wnt target gene EphB2 (274) (Figure 5.7).  
Consistent with these observations and with Wnt pathway suppression in the 
mutants, we also detected significant downregulation of genes encoding other 
shelterin proteins, including Pot1a, Pot1b, and Trf1, in addition to Trf2, in G4 
mTR-/- crypts (Figure 5.7). In addition, similar to Trf2, Pot1a transcript levels were 
also upregulated in response to increasing doses of CHIR99021. We confirm in 
MEFs that TRF2 protein levels are increased with increasing doses of LiCl 
(Figure 5.8).  
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Figure 5.6. Wnt pathway agonists rescue Trf2 and Pot1a expression in 
cultured G4 mTR-/- intestinal organoids. Dose- and time-dependent increase 
of Tfr2 and Pot1a transcript expression as measured by qRT-PCR in WT and G4 
mTR-/- crypts cultured with CHIR99021 for 4 or 8 consecutive days. * p<0.05, ** 
p<0.005, *** p<0.0005, **** p<0.0001. 
 
 
Figure 5.7. Expression of shelterin genes in WT and mTR-/- crypts, and 
distribution of shelterin gene expression in different EphB2-expressing 
crypts. (Top panel) Microarray gene profiling of shelterin genes in WT and G4 
mTerc-/- crypts. (Bottom panel) Microarray gene profiling of shelterin genes in 
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crypt epithelial cells sorting according to surface expression levels of EphB2 
(high, medium or low) (274).  
 
Figure 5.8. Expression of TRF2 protein in MEFs treated with LiCl. Wild-type 
MEFs treated with 0, 5, 10, and 20mM of LiCl were probed for TRF2 (with TRF2 
antibody from Imgenex, IMG-124A) and GAPDH. 
 
With the rescue of shelterin protein expression and tissue fitness with Wnt 
pathway activation, we therefore investigated whether there is an associated 
improvement in telomere capping. We scored telomere dysfunction-induced foci 
(TIFs), measured by colocalization of telomere and 53BP1 foci, and found a 
significant decrease in the number of TIFs in crypts of G4 mTR-/- mice treated 
with Rspo1 (Figure 5.9). Furthermore, Rspo1 treatment reduced anaphase 
bridges, a marker of break-fusion-bridge cycles caused by telomere dysfunction 
(Figure 5.9).  Remarkably, our results therefore suggest that Wnt pathway 
activation is able to rescue uncapped telomeres, even in the absence of 
telomerase.  
TRF2 
GAPDH 
	   LiCl 
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Figure 5.9. Enhanced Wnt signaling rescues telomere capping in G4 mTR-/- 
crypts in vivo. G4 mTR-/- mice treated for eight days with subcutaneous 
injections of R-spondin1 (Rspo1) have reduced telomere dysfunction as 
measured by (top panel) telomere-dysfunction induced foci (TIFs) and (bottom) 
anaphase bridges (arrowheads on left panel; asterisks mark normal anaphases 
in Rspo1-treated mice on right). 120 crypts per mouse from 5 control G4 mice 
and 4 Rspo1-treated G4 mice were surveyed for anaphase bridges, ** p<0.005, 
*** p<0.0005. Scale bars: 10µm (top panel).  
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Telomere capping also depends on telomere length, and Wnt signaling has 
recently been shown to upregulate TERT to elongate telomeres (190), but 
elongation by telomerase is not possible in mTR-/- mice. To rule out telomerase-
independent mechanisms of telomere elongation (i.e. alternative lengthening of 
telomeres, ALT), we compared telomere lengths of treated and untreated G4 
mTR-/- mice using quantitative telomere FISH. Telomere lengths in crypt epithelial 
cells of lithium or Rspo1-treated G4 mTR-/- mice were not longer than those of 
untreated G4 mTR-/- mice (Figure 5.10).  Therefore, the rescue of uncapped 
telomeres is not explained by increased telomere length. Our data indicate that 
Trf2 and Pot1a are Wnt-responsive genes, and raise the possibility that the 
rescue of uncapped telomeres by Wnt pathway activation may be explained by 
an upregulation of shelterin components to improve telomere capping.  
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Figure 5.10. Histogram of telomere fluorescence frequency by Q-FISH 
analysis of intestinal crypts of G4 mTR-/- mice treated with Rspo1 or 
lithium-chow. (A) Three pairs of untreated and Rspo1-treated G4 mTR-/- mice 
were stained and imaged on different days; hence comparisons were not 
averaged. (B) One pair of untreated and Li-treated G4 mTR-/- mice. Mean and SD 
of telomere fluorescence, and the number of nuclei analyzed, are indicated on 
each graph.   
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Wnt pathway suppression in human fibroblasts with telomere dysfunction 
is rescued by Wnt pathway agonists. 
Patients with dyskeratosis congenita (DC) suffer from short telomeres secondary 
to telomerase deficiency, and display gastrointestinal pathology closely 
resembling that seen in late-generataion mTR-/- mice (275). As described in 
Figure 5.11, we analyzed mRNA levels in primary cultured fibroblasts from DC 
patients carrying mutations in the telomerase component dyskerin, and 
compared to primary fibroblasts from healthy controls, DC fibroblasts had 
reduced expression of AXIN2, a direct target of the Wnt pathway (Figure 5.11). 
Levels of TRF2 and POT1 transcripts were also reduced in DC fibroblasts, and 
upon treatment with CHIR99021, the levels of transcripts from all three genes 
were elevated (Figure 5.11). Similar results were obtained for primary Werner 
syndrome (WS) fibroblasts, which also suffer from telomere loss events, but 
which are caused by DNA replication defects that can be rescued by telomerase 
(e.g. from overexpression of hTERT) (120). Indeed, hTERT expression in WS 
cells led to elevated levels of AXIN2, TRF2, and POT1, as did CHIR99021. 
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Figure 5.11. Primary human fibroblasts with telomere dysfunction display 
reduced expression of WNT pathway target genes include shelterins, which 
is rescued by CHIR99021.  Expression of AXIN2, TRF2, and POT1 mRNA 
levels in primary human fibroblasts from three healthy people (WT) and two 
people with dyskeratosis congenita (DC) treated with the indicated levels of 
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CHIR99021 for 48 hours (top three panels), and a person with Werner syndrome 
(WS) infected with retrovirus expressing hTERT or a vector control and treated 
with the indicated levels of CHIR99021 for four days (bottom three panels). * 
p<0.05, ** p<0.005, **** p<0.0001. 
 
DISCUSSION 
The functional importance of the Wnt pathway downregulation in the intestines of 
late generation mTR-/- mice is highlighted by the rescue provided by treatment of 
the mutant mice with Wnt pathway agonists.  Treatment with lithium or Rspo1 
reduces apoptosis, improves epithelial architecture and restores expression of 
Wnt pathway genes.  Similarly, treatment of cultured mutant intestinal organoids 
with Rspo1 or CHIR990201 improves survival, crypt budding, and gene 
expression.  Importantly, components of the Wnt pathway are Wnt target genes 
themselves (e.g. Lgr5, encoding the Rspo1-responsive component of the Wnt 
receptor complex), providing a mechanism by which the effects of Wnt pathway 
agonists can be amplified over time to restore the pathway.  An component of the 
rescue was that telomere capping is reestablished, as indicated by reduced TIF 
levels and complete rescue of anaphase bridges.  The telomere capping is not 
explained by telomere lengthening, but rather is associated with restoration of 
expression of key shelterin genes, including Trf2 and Pot1a.   Suboptimal levels 
of these factors lead to telomere dysfunction (146, 197), and TRF2 
overexpression can cap telomeres that have shortened to the point where they 
would otherwise be uncapped (276). We therefore suggest that restored shelterin 
expression plays a key role in the improved telomere capping and overall rescue.  
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This hypothesis will be explored in future studies, but we note that it is strongly 
supported by the recent demonstration that loss of telomere capping caused by 
diminished Wnt signaling (via reduced β-catenin expression) in human cancer 
cells can be rescued by TRF2 overexpression (196). To see if TRF2 upregulation 
is sufficient to rescue uncapped telomeres and G4 crypt survival, we have begun 
designing experiments to express exogenous TRF2 in G4 organoids (lentiviral 
system) or to upregulate endogenous TRF2 in G4 organoids with statin treatment 
(which has been shown to stimulate TRF2 expression (277)). Regardless of the 
exact mechanisms by which Wnt pathway activation mediates improved telomere 
capping, these findings suggest that telomere capping is influenced by 
extracellular cues, and raise the possibility that disorders in which telomere 
dysfunction plays a pathogenic role (e.g. DC, and perhaps also inflammatory 
bowel diseases and age-related disorders (278, 279)) might be treated by Wnt 
pathway agonists. 
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CHAPTER 6: MOUSE COLONOSCOPY AS A USEFUL TOOL FOR 
TRACKING DISEASE IN MICE 
INTRODUCTION 
Mice are the most commonly used model to study diseases of the GI tract, and 
until most recently, there was no non-lethal way to visualize intestinal pathology – 
the organ in question had to be harvested and processed accordingly, which 
required the mouse to be killed. Owing to the small nature of the mouse and the 
small diameter of the murine colon, endoscopies have not been a convenient 
technique to perform. Instead, indirect measurements that offered hints about GI 
function and pathology (i.e. weight gain/loss, food and water intake/outtake, 
presence of blood in the stool, etc.) are used to track pathology over time in an 
individual mouse. However, these parameters are not sensitive or specific for 
minor or major changes occurring in the GI tract. Endoscopies are a useful tool to 
visualize the gastrointestinal tract for pathology. They are regularly used in 
humans as a modality for diagnostic purposes, for visualization of cancers 
(polyps) or sources of inflammation/bleeding, to track disease progression or 
improvement, among other purposes. In recent years, endoscopic technology in 
small mammals has improved to a point where high-resolution movies and 
images can be consistently obtained from the colon of a living mouse (280). More 
recently, advances to the technology (i.e. flexible sigmoidoscopy) allow us to 
visualize more proximal regions of the colon (281). Chromoendoscopy employs 
the use of dyes as contrast medium with endoscopy (such as methylene blue or 
indigo carmine) and can offer us additional information about the architecture of 
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the colonic crypts, and certain patterns are indicative of certain disease 
processes. Multiple scoring systems exist to allow us to evaluate degrees of 
inflammation, although there is a lack of standardization among the community 
(280, 281). Researchers have been slow to adopt the use of the endoscope to 
assess and track colonic state, since the initial equipment costs are prohibitive 
and there is no established protocol on scoring pathology in mouse colons.  
We want to characterize and track mTR-/- mouse gastrointestinal 
pathology in a non-lethal and relatively non-invasive way over time, since there is 
a lot of variation between age-matched littermates, between generations and age 
of the mice. We also want to see whether the pathology we see on colonoscopy 
is representative of the pathology in the rest of the GI tract. In humans, different 
inflammatory bowel diseases have distinct regions of pathology in the GI tract.  
For example, Crohn’s disease (CD) affects the entire length of the GI tract 
whereas ulcerative colitis (UC) is restricted to the colon. We do not know whether 
GI pathology occurs simultaneously in the mTR-/- small intestine as it does in the 
colon. It is also reasonable to ask whether different parts of the small intestine 
and colon have different degrees of pathology. Since rates of telomere 
shortening depend on the rates of cell division, it is reasonable to propose that 
the onset and degree of GI pathology depends on when telomeres become 
uncapped and is dependent on rates of stem cell proliferation/epithelial turnover 
in different parts of the GI tract.  
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The epithelial turnover rate generally depends in part on the length of the 
crypt-villus distance, and the type and function of the epithelium in question. The 
epithelial turnover rate of the small intestine is around 3-5 days (15 days for 
Paneth cells) (175). The stem cell dynamics of the ascending and descending 
colon are different. There are fewer proliferative stem cells and the cell cycle 
duration is longer in the ascending colon compared to the descending colon 
(282). And since the stem cells are located in the mid-crypt region in the 
ascending colon, there is a bi-directional movement of progeny cells whereas 
there is an lumenal movement of progeny cells from the base of the crypts in the 
descending colon. The turnover rate of the colonic epithelium is about 5 days 
(the ascending colon has deep crypt secretory cells that turnover every 14-21 
days) (238). 
It would useful to correlate the degree of pathology seen with colonoscopy 
to the telomere capping state (measured by TIFs) on histology. If there is good 
correlation between a certain degree of telomere dysfunction to the visualized 
pathology, we will be able to reliably use endoscopic images to assess for the 
progression of telomere dysfunction. We can also use endoscopy to readily see if 
certain factors (e.g. drugs, diets, or introducing a genetic mutation) can help 
prevent or even reverse the observed pathology in late generation mTR-/- mice. If 
we are able to track disease progression/amelioration in one mouse, there is less 
need for large numbers of animals per study to minimize mouse-to-mouse 
differences since it is internally controlled.  
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The intestinal pathology in mTR-/- mice has been somewhat well-
characterized, but has mostly focused on the small intestine. There is certainly 
also disease in the colon of the mTR-/- mice, and it has been described in brief in 
a handful of papers, characterized to the full extent in literature by whole mount 
methylene blue staining of the colon (161). Otherwise, description of the 
pathology is vague, usually describing a loss of crypt numbers, and increased 
inflammation, but beyond that, there is little data. In this section, we outline our 
experimental plans to correlate the pathlogy seen on colonoscopy to that seen 
with histology, including markers of telomere dysfunction, along the length of the 
intestine. We provide preliminary data and give our initial impressions on the 
usefulness and validity of the technique. This part of the thesis was conducted in 
the lab of Arturo Londoño-Vallejo at Institut Curie of France. 
METHODS 
The following procedures were performed at Institut Curie with the collaboration 
and support of Drs. Arturo Londoño-Vallejo and Danijela Matic-Vignjevic.  A 
straight-type rigid miniature Coloview mouse endoscopic system (Karl-Storz) 
(Figure 6.1) linked to a computer with video acquisition software was used to 
visualize and record videos and images of the mouse colon. The setup is as 
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seen in Figure 6.1. 
 
Figure 6.1. Setup of colonoscopy equipment. A straight-type rigid miniature 
Coloview mouse endoscopic system (Karl-Storz) was used. 
After mouse anesthesia with isoflurane administered from a vaporizer 
connected to an enclosed chamber, the mouse anus was lubricated and the 
colon was flushed with a small amount of 1% methylene blue dye, and moved to 
a platform with isoflurane administered through a nose mask. After 3-5 minutes, 
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the colon was flushed with water to clean out any stool or extra methylene blue 
dye. The endoscope probe was introduced to the mid-descending colon, and 
videos and images were recorded. The images were chosen carefully to show 
similar viewpoints in terms of endoscopy camera orientation. Table 4 provides a 
summary of all of the mice we scoped, which includes their genotype, age, sex, 
and other measurements, such as weight and general physical appearance. We 
chose as many littermates as we could of various ages from different genotypes 
(littermates are indicated by the same age). We did not harvest intestines from all 
of the mice we performed colonoscopies on, but for those that we did, we waited 
3-5 days after colonoscopy for the methylene dye to pass, in case the dye 
interfered with downstream histology analyses. We harvested the following 
tissues separately: duodenum, jejunum, ileum, ascending colon and descending 
colon.  
RESULTS 
We surveyed mice of different ages of different genotypes, performing one-time 
colonoscopies and organ harvest a few days later (Table 4). Representative 
images obtained from the colonoscopy will be shown in the following figures as 
described. In the wild-type, mTR+/- (F1), and G1 mTR-/- mice, there were no 
unexpected or remarkable findings in terms of age-inappropriate weight loss or 
pathology in outward appearance. All mice appeared healthy and normal, with no 
physical signs of pathology commonly seen in late generation mTR-/- mice (e.g. 
kyphosis, greying hair, rectal prolapse, diarrhea, etc.). Littermates were of 
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comparable age, with one G1 mouse being slightly heavier than two of its 
littermates.  
Table 6.1. Description of mice that had undergone colonoscopies. Mice of 
different ages (in weeks) of each indicated genotype underwent colonoscopies 
and their general physical appearance were noted (including any findings during 
organ harvest). Their weights (in grams) were taken right before the colonoscopy 
and if their intestines were collected for histology, right before harvest. Lengths of 
small intestines from the duodenum to just before the cecum were measured if 
intestines were collected for histology (in centimeters). 
Genotype 
Age 
(wks) Sex 
Wt 
(g) 
Wt at 
harvest 
Small int 
length 
(cm) Physical appearance 
WT 6 M 16.3 19.4 33 Looks healthy 
WT 47 M 30.4 
  
Looks healthy 
WT 47 M 
 
36.6 32 Looks healthy 
F1 7 M 21.1 
  
Looks healthy 
F1 7 M 21 
  
Looks healthy 
F1 7 M 19.8 
  
Looks healthy 
F1 16 M 29.6 33.7 37 
Looks healthy, peritoneal 
6x6mm mass (sent for histo) 
F1 16 M 30.9 
  
Looks healthy 
F1 30 F 24.6 23.4 33 Looks healthy 
F1 37 M 27.9 
  
Looks healthy 
G1 7 F 16.5   Looks healthy 
G1 7 M 16.7 
  
Looks healthy 
G1 7 M 20.2 
  
Looks healthy 
G1 9 F 17 17.7 33 
Looks healthy, ileum 
epithelium is bumpy/rough 
looking 
G1 39 M 25.5 29.7 28 Looks healthy 
G1 110  23.5   
Looks mainly healthy, minor 
kyphosis 
G2 7 M 20.5   
Looks healthy 
G2 7 M 19.4   
Looks healthy 
G2 7 M 14.5   
Loose stool, otherwise 
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healthy looking 
G2 9 M 21.5 
  
Looks healthy 
G2 9 M 19.5 21.3 32 Looks healthy 
G2 55 M 20.9 21.7 21 Graying hair, kyphosis 
G2 55 F 25.1 24.5 29 Looks healthy 
G2 57 M 20.4 
  
Looks healthy, mild kyphosis 
G2 59 F 18.9 
  
Graying hair, kyphosis, rectal 
prolapse 
G2 70  23   Looks healthy 
G2 70  14.5   Kyphosis 
G3 7 F 13   Looks healthy 
G3 24 F 16.3   Looks healthy 
G3 24 F 13.2   Graying hair, diarrhea 
G3 32 F 21.3 22 35 Alopecia 
G3 32 F 20 
  
Alopecia, crusting around 
rectum 
G3 45 F 18.2 17.7 
 
Graying hair, kyphosis 
G3 45 M 13.1 
  
Looks sick and weak, 
graying hair, small head, 
kyphosis 
G3 59 F 14.7 
  
Looks sick, blood and 
crusting around rectum 
G3 59 F 18.5 18.3 25 Skinny, kyphosis 
G3 70  24.4   Looks healthy 
G3 70  18.3   
Looks sick, kyphosis, 
diarrhea 
G4 7 M 15.8 
  
Looks healthy (failed 
colonoscopy attempt) 
G4 7 M 15.5 17.2 34 Looks healthy 
G4 20  26   Looks healthy 
G4 20  17   Looks healthy 
G4 22 F 14.1 15.3 21 Mild kyphosis 
G4 22 F 14.1 14.8 24 
Looks sick, graying hair, 
kyphosis, bloody rectum, 
diarrhea 
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On colonoscopy (Figure 6.2, only F1 shown), the WT and F1 mice had a nice, 
dense honeycomb crypt pattern, with easy visualization of the underlying 
mucosal blood vessels. However, when comparing a 32-week and a 110-week 
old G1 mTR-/- mouse, there was a drastic difference in the colonoscopy exam. 
Like WT and F1 mice, the 32-week old G1 mouse colon also had a dense 
honeycomb crypt pattern with visible mucosal blood vessels, whereas the 110-
week old G1 mouse colon had major crypt losses, with enlarged crypt lesions, 
loss of blood vessel visualization (Figure 6.3), indicative of severe inflammation 
(280). Given these findings, it seems that endoscopy may be more sensitive at 
detecting age-related pathology than other physical measurements (e.g. weight). 
          
Figure 6.2. Chromoendoscopy images of seven-week old F1 littermate 
colons. Healthy-appearing F1 littermates weighing 21g (left panel) or 19.8g (right 
panel). 
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Figure 6.3. Chromoendoscopy images of G1 mouse colons. Healthy-
appearing G1 mouse of 32 weeks of age weighing 33g (left panel) and a G1 
mouse of 110 weeks of age weighing 23.5g with mild kyphosis (right panel) 
 
 
In the G2 cohort, two out of three of the youngest littermates (seven 
weeks of age) had age-appropriate weights and had a healthy appearance. 
However, one of the littermates had markedly reduced weight and some diarrhea. 
On colonoscopy (Figure 6.4), both of these mice had dense honeycomb crypt 
structures (although perhaps not as dense or organized as the WT or young 
healthy F1/G1 colons) and visualization of underlying blood vessels. In this 
littermate matchup, there was no obvious difference in the pathology as 
assessed by colonoscopy. This is an instance where it would be interesting to 
track these littermates over time to see if weight difference is a good early 
predictor/parameter of: 1) degree of telomere dysfunction, 2) lifespan of the 
individual, and 3) degree of intestinal pathology. 
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Figure 6.4. Chromoendoscopy images of seven-week old G2 littermate 
colons. G2 littermates weighing 20.5g (left panel) or 14.5g with loose stool (right 
panel). 
 
Among the older G2 cohort (55-59 weeks of age), outward signs of 
pathology are more obvious, with the heaviest mouse out of the four having no 
obvious signs of pathology, and the other three all showing signs of kyphosis, 
two of which have greying hair, and the skinniest of the four also with rectal 
prolapse and wasting. Similarly, in the oldest G2 cohort (70-week old littermates), 
one sibling appears healthy while the other has kyphosis and weight loss. On 
colonoscopy (Figure 6.5), these 70-week old G2 littermates both have a loss of 
dense and organized crypt structures and loss of vessel visualization, with the 
smaller and sicker mouse having a more severe colonic pathology. It is 
interesting but perhaps not counterintuitive to see much more severe changes on 
the colonoscopy images than what we can detect from other physical 
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measurements (e.g. weight, appearance, etc). Morever, there is a trending 
correlation between weight, outward appearance, and colonoscopy changes. 
   
Figure 6.5. Chromoendoscopy images of 70-week old G2 littermate colons. 
G2 littermates weighing 23g and healthy-appearing (left panel) or 14.5g with 
kyphosis (right panel). 
 
Among the G3 cohort, there are signs of disease anticipation (where 
pathology shows up earlier in later generations than the earlier generations due 
to the inheritance of shorter telomeres), as seen in the 24-week old G3 mouse 
with diarrhea and greying hair. Interestingly, its slightly larger littermate had no 
outward signs of pathology. Likewise, on colonoscopy, (Figure 6.6), the sicker 
littermate had signs of colonic pathology whereas the healthier littermate had 
very little colonic pathology.  
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Figure 6.6. Chromoendoscopy images of 24-week old G3 littermate colons. 
G3 littermates weighing 16.3g and healthy-appearing (left panel) or 13.2g with 
kyphosis, diarrhea, and greying hair (top and right panels). 
 
In almost all of the G3 mice older than 32 weeks of age, there were signs 
of wasting (age-inappropriate weight loss compared to WT, F1, and G1 mice of 
similar ages) and other late-generation mTR-/- related pathologies, with 
degenerative crypt losses seen with colonoscopy. In the pair of 70-week old 
littermates, one mouse looked healthy while the other had diarrhea and kyphosis. 
As seen in earlier examples, despite a lack of observable gross pathology in the 
110	  
healthier and heavier mouse, the colonoscopy images show clear disease 
(Figure 6.7), and the sicker, skinner mouse had almost a complete loss of crypts.  
     
Figure 6.7. Chromoendoscopy images of 70-week old G3 littermate colons. 
G3 littermates weighing 24.4g and healthy-appearing (left panel) or 18.3g with 
kyphosis, and diarrhea (right panel). 
 
Disease anticipation can also be seen in the G4 cohort, with both of the 
22-week old littermates showing signs of wasting, kyphosis, and one of the two 
mice having diarrhea and rectal bleeding. On colonoscopy (Figure 6.8), both 
mice have comparable levels in the loss of crypts and blood vessel visibility. At 7 
weeks, the two G4 littermates are comparable in weight and outward appearance, 
having no signs of physical pathology. One of the mice had a perforated colon 
during colonoscopy, and we were not able to obtain any useful images. 
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Figure 6.8. Chromoendoscopy images of 22-week old G4 littermate colons. 
G4 littermates weighing 14.1g and kyphosis (left panel) or 14.1g with kyphosis, 
diarrhea, and bloody rectum (right panel). 
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DISCUSSION 
With our survey of cohorts of mice at different ages and genotypes, we are 
beginning to appreciate the huge variations that exist in physical characteristics 
(e.g. weight, kyphosis, diarrhea) and pathology seen with colonoscopy. What is 
clear is that changes in the colon (i.e. loss of vessel visualization, crypt losses 
and aberration) appear before any changes in weight or physical appearance 
occur in mTR-/- mice, which makes sense considering the higher rates of 
environmental insult and epithelium turnover the intestine experiences compared 
to other tissues. What has already been known from literature is the variation in 
telomere lengths between littermates and within a generation of mTR-/- mice, and 
we also see large variation in colon pathology within same generation mTR-/- 
littermates. We will have to confirm and correlate these findings with histological 
analyses (e.g. Q-FISH, TIFs, anaphase bridge counts, etc.). Further, our study 
clearly shows the disease anticipation aspect of mTR-/- pathology, with later 
generations displaying pathology at younger ages. We also see that if you age 
an early generation (110-week old G1) mouse long enough, telomeres can 
shorten critically within an individual to cause pathology. It is unlikely but possible 
that this individual G1 mouse inherited critically short telomeres at birth, and we 
cannot confirm it at this time since we did not perform colonoscopy on this mouse 
when it was younger. But with the advantages of colonoscopy (i.e. non-lethal, 
and we can take sample biopsies), we can longitudinally characterize the colon 
of an individual mouse. Histologic analyses have yet to be performed, but we 
plan to evaluate the H&E staining for general morphology, TUNEL staining for 
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apoptosis measurements, TIF staining for measurements of telomere dysfunction. 
In addition, we hope to be able to find a correlation between degrees of 
pathology seen in different parts of the small intestine to the proximal and distal 
colon and colonoscopy. In summary, we conclude that colonoscopies provide us 
with sensitive approach to evaluate mTR-/- pathology, between littermates, ages, 
and genotypes, or within a single mouse. It also give us a the potential to design 
better experiments in the future by picking mice for experiments based on 
degrees of pathology and not necessarily based on littermates or age-matched 
controls. 	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CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis has further characterized the pathology in the mTR-/- mouse model. 
To summarize our findings, we observe a suppression of Wnt pathway 
components in intestinal crypts of mice with dysfunctional telomeres (late-
generation mTR-/-). Multiple components of the canonical Wnt signaling pathway 
are downregulated in G4 crypts (i.e. ligand, receptor, and downstream effectors), 
which all conspire to downregulate Wnt target gene expression. Specifically, 
there was a dramatic loss of Wnt-responsive ISC marker expression (i.e. Ascl2, 
Sox9, and Lgr5, which mark CBCs) without losses in non-Wnt-responsive ISC 
markers (i.e. Msi1) or apparent losses of crypt cells that are intercalated between 
Paneth cells, which represent the CBC population. Lgr5 is a Wnt target gene but 
also an important Wnt receptor in CBCs, providing positive feedback on Wnt 
signaling, therefore, downregulation of Lgr5 in G4 crypts will further decrease 
Wnt signaling. We (and others) have found evidence that several components of 
the shelterin complex, important in the maintenance of telomere capping, are 
Wnt target genes. Indeed, in G4 crypts, we detect a significant downregulation in 
Trf2 and Pot1a expression, which may add further insult to an already injured 
(uncapped) telomere. This positive feedback between Wnt signaling and 
telomere capping may be an anti-cancer mechanism that a cell with a high 
propensity for genomic instability and carcinogenesis (fast cycling cells with rich 
pro-Wnt signals) has acquired. In the case of the APCMin mouse model, loss of 
wild-type Apc allele causes an unchecked activation of Wnt signaling, eventually 
manifesting as intestinal adenomas that initiate as microadenomas and progress 
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into macroadenomas, resulting in death in 100% of the animals by 4-6 months. 
When the mTR-/- allele is introduced into APCMin mice, there is a decrease in 
survival in G2 and G3 mTR-/-APCMin compared to APCMin, but there is a drastic 
increase in survival at G4 (all the animals survived until sacrifice at 7 months to 
assess tumor burden) (283). The improved survival at G4 mTR-/-APCMin is 
associated with increased microadenomas but reduced macroadenomas, which 
suggests that telomere dysfunction may contribute to genomic instability and 
cancer initiation, but ultimately, advanced telomere dysfunction can set off DNA 
damage responses and apoptosis to halt cancer progression. The authors did not 
assess for Wnt pathway defects in the G4 mTR-/-APCMin intestine, but it is 
plausible that advanced telomere dysfunction halted cancer progression in the 
APCMin model by suppressing Wnt signaling via DNA damage responses.  
The suppression of Wnt signaling appears to be dependent on DNA 
damage responses and p53 activation, and we hypothesize miR-34a activation 
by p53 to be one of the mediators of the Wnt pathway suppression. It is the most 
overexpressed miRNA in the G4 crypt, and it has been shown to promote 
senescence and tumor suppression and suppress multiple components of the 
Wnt pathway. Our preliminary results show a perinatal survival advantage of G4 
mice lacking miR-34a and an increase in survival of G4 miR-34a-/- organoids over 
G4 miR-34a+/+. As we have seen with the endoscopic study in this thesis, there 
are huge natural variations in the phenotypes of these mice, even amongst 
littermates (which is most likely due to the inheritance of different telomere 
lengths), and larger sample sizes are necessary before we can make conclusive 
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statements about the significance of knocking out miR-34a in mTR-/- mice. 
Moreover, since miR-34a has so many different targets, it would be difficult to 
determine exactly what is mediating the rescue downstream of miR-34a. The cell 
has evolved many mechanisms and pathways downstream of DDR to arrest cell 
cycle progression and the accumulation of genomic instability. In fact, a positive 
feedback loop also exists between p53 and miR-34a, where miR-34a inhibits 
Mdm4, an inhibitor of p53. Similarly, inhibition of the Wnt pathway by miR-34a is 
another possible anti-cancer mechanism that has evolved.  
Next, we questioned the functional relevance of the Wnt suppression in 
G4 crypts and hypothesized that supplying exogenous Wnt signals can 
upregulate shelterin proteins Trf2 and Pot1a to improve telomere capping in G4 
crypts. Indeed, we detect a dose-dependent upregulation of Trf2 and Pot1a in 
organoids cultured with Wnt agonists CHIR99021, and G4 mice treated with 
Rspo1 had reduced TIFs and anaphase bridges in their crypt cells. The 
upregulation of Trf2 and Pot1a and the improvement in telomere capping 
corresponded to an improvement in G4 organoid survival, and rescue of CBC 
markers (i.e. Lgr5, Ascl2, and Sox9) in the G4 crypts.  
We present novel findings that demonstrate a mutually supportive 
feedback loop between Wnt signaling and telomere capping, which provides 
insight into how Wnt signaling and telomeres may interact in cancer. Recent 
studies show Wnt signaling to regulate TERT expression, and our study, among 
others, provide evidence for Wnt signaling to regulate shelterin expression.  
Sufficient Wnt signaling can help maintain telomeres in a capped state by 
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regulating shelterin and TERT expression, especially important in cells where 
maintenance of capped telomere is essential.  However, too much Wnt activity 
can be detrimental, as evidenced by inactivating mutations of APC in humans, 
which lead to unchecked Wnt signaling and colorectal cancer.  On the other hand, 
if telomeres become uncapped (i.e. from uncontrolled cell division in 
preneoplastic cells), DNA damage responses are activated to suppress Wnt 
signaling, which in turn suppresses shelterin and TERT expression, reinforcing 
the state of uncapped telomeres. This feedback loop may serve as an anti-
cancer mechanism – Wnt signaling, which can be a pro-cancer signal, is 
suppressed. Furthermore, the reinforced uncapping of telomeres can drive 
preneoplastic cells towards apoptosis. In instances where preneoplastic cells 
with uncapped telomeres escape checkpoint responses, however, uncapped 
telomeres may actually contribute to genomic instability to drive cancers.  
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APPENDIX 
Table A1. Upregulated miRNAs in G4 crypts. miRNAs upregulated in microarray with a q-
value cutoff of 5% 
Transcript	  ID	  
Fold-­‐
Change	  
(G4	  vs.	  
WT)	  
q-­‐value	  
(%)	  
p-­‐value	  
(G4	  vs	  WT)	  
Targets	  experimentally	  
validated/Properly	  
annotated?	  
miR-­‐5097	   9.65	   0.00	   0.00	   tRNA	  
miR-­‐3096b-­‐5p	   9.59	   0.00	   0.00	   misannotation	  
miR-­‐1983	   8.61	   0.00	   0.00	  
dicer	  processed	  from	  alt	  
tRNA	  seq	  
miR-­‐34a	   7.51	   0.00	   0.00	   Yes	  
miR-­‐3472	   7.48	   0.00	   0.00	   No	  
miR-­‐712-­‐star	   6.93	   0.00	   0.00	  
712	  form	  is	  potential	  
biomarker	  for	  
atherosclerosis	  
miR-­‐3473b	   6.25	   0.00	   0.00	   No	  
miR-­‐122	   5.96	   0.45	   0.01	   Yes	  
miR-­‐2137	   5.34	   0.00	   0.00	   No	  
miR-­‐3096b-­‐3p	   5.32	   0.81	   0.02	   misannotation	  
miR-­‐195-­‐star	   5.07	   2.46	   0.06	   Yes	  
miR-­‐5122	   4.82	   0.00	   0.00	   No	  
miR-­‐326-­‐star	   4.80	   0.00	   0.00	   Yes	  
miR-­‐23a-­‐star	   4.79	   0.45	   0.01	   Yes	  
miR-­‐3473	   4.58	   0.00	   0.00	   Multiple	  forms	  (a-­‐g)	  exist	  
miR-­‐3093-­‐3p	   4.39	   0.00	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐3096-­‐3p	   4.36	   0.45	   0.01	   misannotation	  
miR-­‐711	   4.35	   0.00	   0.00	   No	  
miR-­‐92b-­‐star	   4.05	   0.00	   0.00	   Yes	  
miR-­‐5115	   3.88	   0.45	   0.01	   fragment	  of	  LSU	  rRNA	  
miR-­‐1906	   3.88	   0.00	   0.00	   No	  
miR-­‐762	   3.87	   0.00	   0.00	   No	  
miR-­‐714	   3.58	   0.00	   0.00	   No	  
miR-­‐135a-­‐1-­‐
star	   3.58	   0.00	   0.00	   Yes	  
miR-­‐16-­‐1-­‐star	   3.58	   1.28	   0.03	   Yes	  
miR-­‐1982-­‐star	   3.51	   0.00	   0.00	   No	  
miR-­‐712	   3.51	   0.00	   0.00	  
712	  form	  is	  potential	  
biomarker	  for	  
atherosclerosis	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miR-­‐1894-­‐3p	   3.45	   0.00	   0.00	   No	  
miR-­‐1224	   3.42	   0.00	   0.00	  
No,	  but	  confirmed	  by	  
extensive	  cloning	  
miR-­‐298	   3.34	   0.00	   0.00	   Yes	  
miR-­‐1249-­‐star	   3.32	   0.45	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐3096-­‐5p	   3.27	   0.45	   0.01	   misannotation	  
miR-­‐223	   3.26	   2.81	   0.06	   Yes	  
miR-­‐1949	   3.21	   0.45	   0.01	   No	  
miR-­‐5130	   3.20	   0.00	   0.00	  
dicer	  processed	  from	  alt	  
tRNA	  seq	  
miR-­‐3104-­‐5p	   3.16	   0.00	   0.00	   No	  
miR-­‐5131	   3.15	   0.45	   0.01	   No	  
miR-­‐1893	   3.10	   0.45	   0.00	   No	  
miR-­‐1945	   3.08	   0.00	   0.00	   No	  
miR-­‐134	   3.08	   0.45	   0.01	   Yes	  
miR-­‐210	   3.05	   1.50	   0.03	   Yes	  
miR-­‐3067-­‐star	   3.03	   1.65	   0.04	   No	  
miR-­‐34a-­‐star	   2.99	   1.06	   0.02	   Yes	  
miR-­‐874	   2.99	   0.45	   0.01	   Yes	  
miR-­‐1946b	   2.94	   0.45	   0.01	   No	  
miR-­‐1956	   2.82	   1.28	   0.03	   No	  
miR-­‐5109	   2.79	   0.00	   0.00	   fragment	  of	  LSU	  rRNA	  
miR-­‐128-­‐2-­‐star	   2.75	   3.07	   0.06	   Yes	  128	  
miR-­‐150-­‐star	   2.71	   0.45	   0.01	   Yes,	  150	  
miR-­‐3100-­‐5p	   2.68	   0.81	   0.01	   No	  
miR-­‐125a-­‐3p	   2.67	   2.46	   0.05	   Yes,	  mir-­‐10	  family	  
miR-­‐669f-­‐5p	   2.65	   1.80	   0.04	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐696	   2.64	   1.80	   0.04	   No	  
miR-­‐1903	   2.61	   0.00	   0.00	   No	  
miR-­‐669m-­‐5p	   2.60	   1.06	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐211-­‐star	   2.57	   0.00	   0.00	   Yes	  
miR-­‐328-­‐star	   2.56	   0.45	   0.01	   Yes	  
miR-­‐3077-­‐star	   2.54	   0.00	   0.00	   No	  
miR-­‐1247-­‐star	   2.49	   0.45	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐3102-­‐star	   2.47	   0.00	   0.00	   No	  
miR-­‐5128	   2.47	   0.45	   0.00	   No	  
miR-­‐323-­‐5p	   2.46	   0.00	   0.00	   No,	  but	  belongs	  to	  mir-­‐154	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family	  
miR-­‐199b-­‐star	   2.45	   2.46	   0.05	   Yes	  
miR-­‐346-­‐star	   2.42	   0.45	   0.00	   Yes	  
miR-­‐760-­‐3p	   2.38	   0.00	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐24-­‐2-­‐star	   2.36	   0.45	   0.01	   Yes	  
miR-­‐504-­‐star	   2.36	   4.77	   0.09	  
Yes,	  -­‐504	  form	  negatively	  
reg	  p53	  
miR-­‐27a	   2.36	   0.00	   0.00	   Yes	  
miR-­‐3092	   2.34	   0.45	   0.01	   No	  
miR-­‐370	   2.34	   2.81	   0.05	   Yes	  
miR-­‐770-­‐3p	   2.32	   0.45	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐677-­‐star	   2.32	   0.81	   0.02	   No	  
miR-­‐1943	   2.30	   0.45	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐615-­‐5p	   2.30	   2.81	   0.05	   Yes	  
miR-­‐3090-­‐star	   2.30	   0.45	   0.01	   No	  
miR-­‐149-­‐star	   2.28	   0.00	   0.00	   Yes,	  149	  
miR-­‐3113	   2.28	   0.81	   0.02	   No	  
miR-­‐5120	   2.26	   0.00	   0.00	   No	  
miR-­‐92a-­‐2-­‐star	   2.26	   0.45	   0.01	   Yes	  
miR-­‐23a	   2.24	   0.00	   0.00	   Yes	  
miR-­‐668	   2.23	   0.45	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐1940	   2.22	   2.46	   0.04	   No	  
miR-­‐494	   2.19	   0.81	   0.02	   No	  
miR-­‐2182	   2.16	   1.28	   0.02	   No	  
miR-­‐466j	   2.16	   2.46	   0.05	   No	  
miR-­‐193b-­‐star	   2.14	   0.45	   0.00	   Yes	  
miR-­‐129-­‐5p	   2.13	   2.81	   0.05	   Yes	  
miR-­‐297a	   2.10	   1.28	   0.02	   Yes	  
miR-­‐212-­‐3p	   2.09	   1.06	   0.02	   Yes	  
miR-­‐214	   2.08	   0.45	   0.01	   Yes	  
miR-­‐466f	   2.06	   0.45	   0.01	   No	  
miR-­‐1946a	   2.06	   0.81	   0.01	   No	  
miR-­‐3087-­‐star	   2.05	   0.00	   0.00	   No	  
miR-­‐22	   2.05	   0.45	   0.01	   Yes	  
miR-­‐2136	   2.02	   4.77	   0.07	   No	  
miR-­‐5119	   2.00	   1.80	   0.04	   No	  
miR-­‐720	   2.00	   3.80	   0.07	   fragment	  of	  tRNA	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miR-­‐27a-­‐star	   1.99	   2.46	   0.04	   Yes	  
miR-­‐718	   1.98	   0.00	   0.00	   No	  
miR-­‐2861	   1.94	   0.00	   0.00	   Yes,	  clustered	  with	  3960	  
miR-­‐5126	   1.93	   0.00	   0.00	   No	  
miR-­‐466m-­‐5p	   1.92	   3.07	   0.06	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐204-­‐star	   1.92	   1.80	   0.04	   Yes	  
miR-­‐1199	   1.92	   3.07	   0.05	   No	  
miR-­‐3960	   1.90	   0.00	   0.00	   Yes	  
miR-­‐705	   1.89	   0.45	   0.01	   No	  
miR-­‐1892	   1.89	   1.06	   0.02	   No	  
miR-­‐3091-­‐5p	   1.88	   0.00	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐497	   1.88	   3.07	   0.06	   Yes	  
miR-­‐678	   1.87	   0.45	   0.00	   No	  
miR-­‐29b-­‐2-­‐star	   1.87	   2.46	   0.04	   Yes	  
miR-­‐5111	   1.85	   1.50	   0.03	   fragment	  of	  tRNA	  
miR-­‐132	   1.85	   0.45	   0.01	   Yes	  
miR-­‐5105	   1.85	   0.45	   0.00	   fragment	  of	  LSU	  rRNA	  
miR-­‐1934-­‐star	   1.83	   0.45	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐667	   1.82	   2.81	   0.05	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐365-­‐2-­‐star	   1.81	   0.45	   0.01	   Yes	  
miR-­‐290-­‐5p	   1.81	   3.80	   0.06	   Yes	  
miR-­‐199b	   1.78	   1.28	   0.02	   Yes	  
miR-­‐199a-­‐5p	   1.77	   3.80	   0.06	   Yes	  
miR-­‐690	   1.77	   0.00	   0.00	   No	  
miR-­‐3061-­‐5p	   1.77	   3.80	   0.07	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐5121	   1.76	   0.45	   0.01	   No	  
miR-­‐199a-­‐3p	   1.74	   1.50	   0.02	   Yes	  
miR-­‐195	   1.73	   1.28	   0.02	   Yes	  
miR-­‐5132	   1.71	   1.28	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐21-­‐star	   1.70	   1.28	   0.02	   Yes	  
miR-­‐505-­‐5p	   1.69	   1.65	   0.02	   Yes	  
miR-­‐3470a	   1.68	   1.80	   0.03	   No	  
miR-­‐675-­‐5p	   1.66	   3.07	   0.05	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐99b	   1.65	   3.07	   0.05	   Yes	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miR-­‐1199-­‐star	   1.64	   3.07	   0.05	   No	  
miR-­‐1931	   1.64	   1.06	   0.01	   No	  
miR-­‐126-­‐3p	   1.63	   2.46	   0.03	   Yes	  
miR-­‐432	   1.62	   1.28	   0.02	   No	  
miR-­‐296-­‐3p	   1.62	   0.45	   0.01	   Yes	  
miR-­‐598-­‐star	   1.61	   1.80	   0.03	  
No,	  but	  high	  annotation	  
confidence	  
let-­‐7e	   1.60	   1.06	   0.01	   Yes	  
miR-­‐665-­‐star	   1.59	   1.28	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐5099	   1.59	   3.07	   0.05	   No	  
miR-­‐3098-­‐3p	   1.56	   0.45	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐292-­‐5p	   1.56	   1.80	   0.03	   Yes	  
miR-­‐5106	   1.56	   0.45	   0.00	   No	  
miR-­‐203	   1.55	   0.45	   0.01	   Yes	  
miR-­‐339-­‐3p	   1.53	   3.07	   0.05	   Yes	  
miR-­‐18a	   1.53	   2.46	   0.03	   Yes	  
miR-­‐3081-­‐star	   1.53	   3.80	   0.05	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐3077	   1.52	   1.06	   0.01	   No	  
miR-­‐24	   1.52	   0.45	   0.00	   Yes	  
miR-­‐128-­‐1-­‐star	   1.51	   3.80	   0.05	   Yes	  128	  
miR-­‐5102	   1.47	   3.07	   0.04	   probably	  28S	  rRNA	  
miR-­‐296-­‐5p	   1.46	   1.80	   0.03	   Yes	  
miR-­‐763	   1.40	   1.80	   0.02	   No	  
miR-­‐344g-­‐3p	   1.40	   4.77	   0.06	   No	  
miR-­‐1196	   1.38	   2.81	   0.03	  
misannotation	  (Alu/B1	  SINE	  
element)	  
miR-­‐212-­‐5p	   1.37	   1.65	   0.01	   Yes	  
miR-­‐1195	   1.37	   2.46	   0.02	   No	  
miR-­‐3076-­‐3p	   1.36	   4.77	   0.05	   No	  
miR-­‐138	   1.35	   3.07	   0.04	   Yes	  
let-­‐7b-­‐star	   1.34	   1.06	   0.01	   Yes	  
miR-­‐3065	   1.33	   3.07	   0.03	   No	  
miR-­‐3102-­‐5p.2	   1.33	   3.80	   0.04	   No	  
miR-­‐1247	   1.30	   3.80	   0.04	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐1188	   1.29	   1.28	   0.01	   No	  
miR-­‐467h	   1.26	   3.80	   0.03	   No	  
miR-­‐744	   1.25	   0.45	   0.00	   Yes	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miR-­‐3093-­‐5p	   1.23	   2.81	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
 
Table A2. Downregulated miRNAs in G4 crypts. miRNAs downregulated in microarray with 
a q-value cutoff of 5% 
Transcript	  ID	  
Fold-­‐
Change	  
(G4	  vs.	  
WT)	   q-­‐value	  (%)	  
p-­‐value	  
(G4	  vs	  
WT)	  
Targets	  experimentally	  
validated/Properly	  
annotated?	  
let-­‐7b	   -­‐1.18	   1.65	   0.00	   Yes	  
let-­‐7f	   -­‐1.42	   0.87	   0.00	   Yes	  
let-­‐7i-­‐star	   -­‐1.56	   3.80	   0.03	   Yes	  
miR-­‐103	   -­‐1.17	   3.80	   0.00	   Yes	  
miR-­‐106b-­‐star	   -­‐1.41	   1.28	   0.00	   Yes	  
miR-­‐10a	   -­‐2.08	   0.84	   0.00	   Yes,	  mir-­‐10	  family	  
miR-­‐10a-­‐star	   -­‐3.96	   0.00	   0.00	   Yes,	  mir-­‐10	  family	  
miR-­‐10b	   -­‐1.89	   0.84	   0.00	   Yes,	  mir-­‐10	  family	  
miR-­‐1198-­‐5p	   -­‐1.43	   1.09	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐130b	   -­‐1.70	   0.84	   0.00	   Yes	  
miR-­‐130b-­‐star	   -­‐2.69	   1.28	   0.02	   Yes	  
miR-­‐139-­‐5p	   -­‐2.40	   1.50	   0.02	   Yes	  
miR-­‐140-­‐star	   -­‐1.25	   2.81	   0.01	   Yes	  
miR-­‐141	   -­‐1.84	   0.84	   0.00	   Yes	  
miR-­‐144	   -­‐1.29	   1.65	   0.00	   Yes	  
miR-­‐148a	   -­‐2.30	   0.87	   0.01	   Yes	  
miR-­‐150	   -­‐5.25	   2.81	   0.04	   Yes	  
miR-­‐151-­‐3p	   -­‐1.41	   2.46	   0.01	   Yes	  
miR-­‐151-­‐5p	   -­‐1.27	   1.09	   0.00	   Yes	  
miR-­‐152	   -­‐1.82	   2.46	   0.02	   Yes	  
miR-­‐15a	   -­‐1.58	   0.84	   0.00	   Yes	  
miR-­‐15b	   -­‐1.40	   1.50	   0.01	   Yes	  
miR-­‐16	   -­‐1.30	   0.87	   0.00	   Yes	  
miR-­‐17-­‐star	   -­‐1.36	   1.65	   0.01	   Yes	  
miR-­‐181a	   -­‐4.20	   0.00	   0.00	   Yes	  
miR-­‐181b	   -­‐4.53	   0.00	   0.00	   Yes	  
miR-­‐181b-­‐1-­‐
star	   -­‐1.18	   3.80	   0.01	   Yes	  
miR-­‐181c	   -­‐5.84	   0.00	   0.00	   Yes	  
miR-­‐181c-­‐star	   -­‐3.30	   0.84	   0.00	   Yes	  
miR-­‐181d	   -­‐3.22	   0.00	   0.00	   Yes	  
124	  
miR-­‐1839-­‐5p	   -­‐1.67	   0.87	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐187	   -­‐2.15	   1.65	   0.02	   Yes	  
miR-­‐18b	   -­‐1.39	   1.09	   0.00	   Yes	  
miR-­‐190b-­‐star	   -­‐1.43	   4.77	   0.03	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐192-­‐star	   -­‐1.47	   0.87	   0.00	   Yes	  
miR-­‐194-­‐2-­‐star	   -­‐1.46	   3.80	   0.02	   Yes	  
miR-­‐196a-­‐1-­‐
star	   -­‐3.29	   2.46	   0.03	   Yes	  
miR-­‐19b	   -­‐1.34	   2.46	   0.01	   Yes	  
miR-­‐200a	   -­‐1.94	   0.00	   0.00	   Yes	  
miR-­‐200a-­‐star	   -­‐1.55	   1.65	   0.01	   Yes	  
miR-­‐200b	   -­‐1.53	   0.84	   0.00	   Yes	  
miR-­‐200b-­‐star	   -­‐1.47	   0.84	   0.00	   Yes	  
miR-­‐206	   -­‐1.24	   3.80	   0.01	   Yes	  
miR-­‐20b	   -­‐1.98	   0.00	   0.00	   Yes	  
miR-­‐221	   -­‐1.31	   4.77	   0.02	   Yes	  
miR-­‐222	   -­‐1.51	   2.46	   0.02	   Yes	  
miR-­‐224	   -­‐1.80	   2.81	   0.02	   Yes	  
miR-­‐23b	   -­‐1.28	   1.09	   0.00	   Yes	  
miR-­‐25	   -­‐1.86	   0.00	   0.00	   Yes	  
miR-­‐26a	   -­‐1.36	   0.00	   0.00	   Yes	  
miR-­‐26b	   -­‐1.86	   0.84	   0.00	   Yes	  
miR-­‐27b	   -­‐1.21	   3.07	   0.01	   Yes	  
miR-­‐28-­‐star	   -­‐1.29	   2.81	   0.01	   Yes	  
miR-­‐28c	   -­‐1.59	   2.46	   0.02	   Yes	  
miR-­‐295-­‐star	   -­‐1.25	   4.77	   0.02	   Yes	  
miR-­‐29b	   -­‐2.08	   1.09	   0.01	   Yes	  
miR-­‐29c	   -­‐2.54	   0.84	   0.00	   Yes	  
miR-­‐3089-­‐3p	   -­‐1.27	   3.07	   0.01	   No	  
miR-­‐30a	   -­‐1.81	   0.00	   0.00	   Yes	  
miR-­‐30a-­‐star	   -­‐2.23	   1.65	   0.02	   Yes	  
miR-­‐30b	   -­‐1.80	   0.00	   0.00	   Yes	  
miR-­‐30b-­‐star	   -­‐1.91	   0.84	   0.00	   Yes	  
miR-­‐30c	   -­‐1.55	   0.84	   0.00	   Yes	  
miR-­‐30c-­‐2-­‐star	   -­‐2.80	   0.87	   0.01	   Yes	  
miR-­‐30d	   -­‐1.78	   0.00	   0.00	   Yes	  
miR-­‐30e	   -­‐2.76	   0.00	   0.00	   Yes	  
miR-­‐30e-­‐star	   -­‐2.22	   0.84	   0.00	   Yes	  
miR-­‐31-­‐star	   -­‐1.68	   2.46	   0.02	   Yes	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miR-­‐3105-­‐3p	   -­‐2.80	   0.00	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐3105-­‐5p	   -­‐3.05	   1.65	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐320	   -­‐1.75	   1.28	   0.01	   Yes	  
miR-­‐324-­‐3p	   -­‐2.23	   0.87	   0.01	   Yes	  
miR-­‐326	   -­‐1.88	   2.46	   0.02	   Yes	  
miR-­‐340-­‐5p	   -­‐1.52	   2.81	   0.02	   Yes	  
miR-­‐342-­‐3p	   -­‐2.19	   0.00	   0.00	   Yes	  
miR-­‐342-­‐5p	   -­‐2.83	   1.09	   0.01	   Yes	  
miR-­‐34b-­‐5p	   -­‐1.43	   2.46	   0.01	   Yes	  
miR-­‐350	   -­‐1.74	   0.84	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐363-­‐3p	   -­‐6.62	   0.84	   0.00	   Yes	  
miR-­‐363-­‐5p	   -­‐6.78	   0.00	   0.00	   Yes	  
miR-­‐374	   -­‐3.00	   0.87	   0.01	   Yes,	  activates	  Wnt	  signaling	  
miR-­‐375	   -­‐1.70	   3.07	   0.03	   Yes	  
miR-­‐375-­‐star	   -­‐1.34	   4.77	   0.03	   Yes	  
miR-­‐378-­‐star	   -­‐1.34	   2.46	   0.01	   Yes	  
miR-­‐378b	   -­‐1.50	   2.81	   0.02	   No	  
miR-­‐3962	   -­‐1.27	   4.77	   0.02	   No	  
miR-­‐411-­‐star	   -­‐1.31	   1.80	   0.01	   Yes	  
miR-­‐433-­‐star	   -­‐1.24	   1.65	   0.00	   Yes	  
miR-­‐450a-­‐1-­‐
star	   -­‐1.32	   0.84	   0.00	   Yes	  
miR-­‐466p-­‐3p	   -­‐1.49	   3.80	   0.03	   No	  
miR-­‐467a	   -­‐2.53	   3.80	   0.05	   Yes	  
miR-­‐467a-­‐star	   -­‐1.96	   1.80	   0.02	   Yes	  
miR-­‐493-­‐star	   -­‐1.41	   1.65	   0.01	   Yes	  
miR-­‐532-­‐3p	   -­‐1.63	   1.80	   0.01	   Yes	  
miR-­‐532-­‐5p	   -­‐1.23	   3.80	   0.01	   Yes	  
miR-­‐543	   -­‐1.34	   4.77	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐574-­‐3p	   -­‐2.14	   0.87	   0.01	   Yes,	  activates	  Wnt	  signaling	  
miR-­‐652	   -­‐1.49	   0.87	   0.00	   Yes	  
miR-­‐676	   -­‐3.29	   0.84	   0.00	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐700-­‐star	   -­‐1.45	   2.81	   0.02	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐7a-­‐1-­‐star	   -­‐3.48	   1.09	   0.01	   Yes	  
miR-­‐802	   -­‐1.42	   3.07	   0.02	   Yes	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miR-­‐871-­‐3p	   -­‐1.36	   2.46	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐872	   -­‐1.89	   1.65	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐883a-­‐3p	   -­‐1.24	   3.80	   0.01	  
No,	  but	  high	  annotation	  
confidence	  
miR-­‐92a	   -­‐1.66	   0.84	   0.00	   Yes	  
miR-­‐92b	   -­‐1.79	   0.84	   0.00	   Yes	  
miR-­‐93	   -­‐1.23	   1.65	   0.00	   Yes	  
miR-­‐93-­‐star	   -­‐1.78	   0.00	   0.00	   Yes	  
miR-­‐96	   -­‐2.06	   0.87	   0.01	   Yes	  
miR-­‐99a	   -­‐2.11	   0.84	   0.00	   Yes,	  mir-­‐10	  family	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